UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
(Mark One) |
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
Commission File Number:
(Exact name of registrant as specified in its charter)
(State of incorporation) |
(I.R.S. Employer Identification No.) |
|
|
(Address of principal executive offices) |
(Zip Code) |
(
(Registrant’s telephone number, including area code)
Securities Registered Pursuant to Section 12(b) of the Act:
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered |
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. Refer to the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b‑2 of the Exchange Act.
Large accelerated filer ☐ |
Accelerated filer ☐ |
Smaller reporting company |
|
Emerging growth company |
|
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b‑2 of the Exchange Act). Yes ☐ No
The issuer had
RUNWAY GROWTH FINANCE CORP.
FORM 10‑Q FOR THE QUARTER ENDED September 30, 2023
Table of Contents
PART I. FINANCIAL INFORMATION
Item 1. Financial Statements
RUNWAY GROWTH FINANCE CORP.
Statements of Assets and Liabilities
(In thousands, except share and per share data)
|
|
September 30, 2023 |
|
|
December 31, 2022 |
|
||||
|
|
(Unaudited) |
|
|
|
|
||||
Assets |
|
|
|
|
|
|
|
|
||
Investments at fair value: |
|
|
|
|
|
|
|
|
||
Non-control/non-affiliate investments at fair value (cost of $ |
|
$ |
|
|
|
$ |
|
|
||
Affiliate investments at fair value (cost of $ |
|
|
|
|
|
|
|
|
||
Control investments at fair value (cost of $ |
|
|
|
|
|
|
|
|
||
Total investments at fair value (cost of $ |
|
|
|
|
|
|
|
|
||
Cash and cash equivalents |
|
|
|
|
|
|
|
|
||
Interest and fees receivable |
|
|
|
|
|
|
|
|
||
Other assets |
|
|
|
|
|
|
|
|
||
Total assets |
|
|
|
|
|
|
|
|
||
Liabilities |
|
|
|
|
|
|
|
|
||
Debt: |
|
|
|
|
|
|
|
|
||
Credit facility |
|
|
|
|
|
|
|
|
||
2026 Notes |
|
|
|
|
|
|
|
|
||
2027 Notes |
|
|
|
|
|
|
|
|
||
Unamortized deferred debt costs |
|
|
|
( |
) |
|
|
|
( |
) |
Total debt, less unamortized deferred debt costs |
|
|
|
|
|
|
|
|
||
Incentive fees payable |
|
|
|
|
|
|
|
|
||
Interest payable |
|
|
|
|
|
|
|
|
||
Accrued expenses and other liabilities |
|
|
|
|
|
|
|
|
||
Total liabilities |
|
|
|
|
|
|
|
|
||
|
|
|
|
|
|
|
|
|||
Net assets |
|
|
|
|
|
|
|
|
||
Common stock, par value |
|
|
|
|
|
|
|
|
||
Additional paid-in capital |
|
|
|
|
|
|
|
|
||
Distributable earnings (losses) |
|
|
|
( |
) |
|
|
|
( |
) |
Treasury stock |
|
|
|
( |
) |
|
|
|
( |
) |
Total net assets |
|
$ |
|
|
|
$ |
|
|
||
|
|
|
|
|
|
|
|
|
||
Shares of common stock outstanding ($ |
|
|
|
|
|
|
|
|
||
Net asset value per share |
|
$ |
|
|
|
$ |
|
|
See notes to financial statements.
1
RUNWAY GROWTH FINANCE CORP.
Statements of Operations
(Unaudited)
(In thousands, except share and per share data)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
|
Three Months Ended September 30, |
|
|
Nine Months Ended September 30, |
|
||||||||||||||
|
|
2023 |
|
|
2022 |
|
|
2023 |
|
|
2022 |
|
||||||||
Investment income |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
From non-control/non-affiliate investments: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Interest income |
|
$ |
|
|
|
$ |
|
|
|
$ |
|
|
|
$ |
|
|
||||
Payment-in-kind interest income |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Dividend income |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Fee income |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
From affiliate investments: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Interest income |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Payment-in-kind interest income |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Fee income |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
From control investments: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Interest income |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Payment-in-kind interest income |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Other income |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Total investment income |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Operating expenses |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Management fees |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Incentive fees |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Interest and other debt financing expenses |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Professional fees |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Administration agreement expenses |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Insurance expense |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Tax expense |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Other expenses |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Total operating expenses |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Net investment income |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Net realized and net change in unrealized gain (loss) on investments |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Net realized gain (loss) on non-control/non-affiliate investments |
|
|
|
|
|
|
|
|
|
|
|
( |
) |
|
|
|
|
|||
Net realized gain (loss) on investments |
|
|
|
|
|
|
|
|
|
|
|
( |
) |
|
|
|
|
|||
Net change in unrealized gain (loss) on non-control/non-affiliate investments |
|
|
|
( |
) |
|
|
|
( |
) |
|
|
|
( |
) |
|
|
|
( |
) |
Net change in unrealized gain (loss) on affiliate investments |
|
|
|
|
|
|
|
( |
) |
|
|
|
( |
) |
|
|
|
( |
) |
|
Net change in unrealized gain (loss) on control investments |
|
|
|
|
|
|
|
( |
) |
|
|
|
|
|
|
|
( |
) |
||
Net change in unrealized gain (loss) on investments |
|
|
|
( |
) |
|
|
|
( |
) |
|
|
|
( |
) |
|
|
|
( |
) |
Net realized and unrealized gain (loss) on investments |
|
|
|
( |
) |
|
|
|
( |
) |
|
|
|
( |
) |
|
|
|
( |
) |
Net increase (decrease) in net assets resulting from operations |
|
$ |
|
|
|
$ |
|
|
|
$ |
|
|
|
$ |
|
|
||||
Net investment income per common share (basic and diluted) |
|
$ |
|
|
|
$ |
|
|
|
$ |
|
|
|
$ |
|
|
||||
Net increase (decrease) in net assets resulting from operations per common share (basic and diluted) |
|
$ |
|
|
|
$ |
|
|
|
$ |
|
|
|
$ |
|
|
||||
Weighted average shares outstanding (basic and diluted) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
See notes to financial statements.
2
RUNWAY GROWTH FINANCE CORP.
Statements of Changes in Net Assets
(Unaudited)
(In thousands, except share and per share data)
|
|
|
Common Stock |
|
|
|
|
|
|
Paid-in Capital |
|
|
Accumulated |
|
|
|
|
|
||||||||||||
For the Three Months Ended September 30, 2023 |
|
Shares (1) |
|
|
Amount |
|
|
Treasury Stock |
|
|
in Excess of Par Value |
|
|
Undistributed Earnings (Losses) |
|
|
Total Net Assets |
|
||||||||||||
Balances at June 30, 2023 |
|
|
|
|
$ |
|
|
|
$ |
|
( |
) |
|
$ |
|
|
|
$ |
|
( |
) |
|
$ |
|
|
|||||
Net increase (decrease) in net assets resulting from operations |
|
|
— |
|
|
|
|
— |
|
|
|
|
— |
|
|
|
|
— |
|
|
|
|
|
|
|
|
|
|||
Issuance of common stock |
|
|
— |
|
|
|
|
— |
|
|
|
|
— |
|
|
|
|
— |
|
|
|
|
— |
|
|
|
|
— |
|
|
Acquisition of treasury shares |
|
|
— |
|
|
|
|
— |
|
|
|
|
— |
|
|
|
|
— |
|
|
|
|
— |
|
|
|
|
— |
|
|
Refunds (payments) of offering costs |
|
|
— |
|
|
|
|
— |
|
|
|
|
— |
|
|
|
|
— |
|
|
|
|
— |
|
|
|
|
— |
|
|
Dividends paid to stockholders |
|
|
— |
|
|
|
|
— |
|
|
|
|
— |
|
|
|
|
— |
|
|
|
|
( |
) |
|
|
|
( |
) |
|
Balances at September 30, 2023 |
|
|
|
|
$ |
|
|
|
$ |
|
( |
) |
|
$ |
|
|
|
$ |
|
( |
) |
|
$ |
|
|
|
|
|
Common Stock |
|
|
|
|
|
|
Paid-in Capital |
|
|
Accumulated |
|
|
|
|
|
||||||||||||
For the Nine Months Ended September 30, 2023 |
|
Shares (1) |
|
|
Amount |
|
|
Treasury Stock |
|
|
in Excess of Par Value |
|
|
Undistributed Earnings (Losses) |
|
|
Total Net Assets |
|
||||||||||||
Balances at December 31, 2022 |
|
|
|
|
$ |
|
|
|
$ |
|
( |
) |
|
$ |
|
|
|
$ |
|
( |
) |
|
$ |
|
|
|||||
Net increase (decrease) in net assets resulting from operations |
|
|
— |
|
|
|
|
— |
|
|
|
|
— |
|
|
|
|
— |
|
|
|
|
|
|
|
|
|
|||
Issuance of common stock |
|
|
— |
|
|
|
|
— |
|
|
|
|
— |
|
|
|
|
— |
|
|
|
|
— |
|
|
|
|
— |
|
|
Acquisition of treasury shares |
|
|
— |
|
|
|
|
— |
|
|
|
|
— |
|
|
|
|
— |
|
|
|
|
— |
|
|
|
|
— |
|
|
Refunds (payments) of offering costs |
|
|
— |
|
|
|
|
— |
|
|
|
|
— |
|
|
|
|
— |
|
|
|
|
— |
|
|
|
|
— |
|
|
Dividends paid to stockholders |
|
|
— |
|
|
|
|
— |
|
|
|
|
— |
|
|
|
|
— |
|
|
|
|
( |
) |
|
|
|
( |
) |
|
Balances at September 30, 2023 |
|
|
|
|
$ |
|
|
|
$ |
|
( |
) |
|
$ |
|
|
|
$ |
|
( |
) |
|
$ |
|
|
(1) |
Number of shares is shown net of cumulative treasury stock repurchases of |
|
|
|
Common Stock |
|
|
|
|
|
|
Paid-in Capital |
|
|
Accumulated |
|
|
|
|
|
||||||||||||
For the Three Months Ended September 30, 2022 |
|
Shares (1) |
|
|
Amount |
|
|
Treasury Stock |
|
|
in Excess of Par Value |
|
|
Undistributed Earnings (Losses) |
|
|
Total Net Assets |
|
||||||||||||
Balances at June 30, 2022 |
|
|
|
|
$ |
|
|
|
$ |
|
( |
) |
|
$ |
|
|
|
$ |
|
( |
) |
|
$ |
|
|
|||||
Net increase (decrease) in net assets resulting from operations |
|
|
— |
|
|
|
|
— |
|
|
|
|
— |
|
|
|
|
— |
|
|
|
|
|
|
|
|
|
|||
Issuance of common stock |
|
|
— |
|
|
|
|
— |
|
|
|
|
— |
|
|
|
|
— |
|
|
|
|
— |
|
|
|
|
— |
|
|
Acquisition of treasury shares |
|
|
( |
) |
|
|
|
— |
|
|
|
|
( |
) |
|
|
|
— |
|
|
|
|
— |
|
|
|
|
( |
) |
|
Refunds (payments) of offering costs |
|
|
— |
|
|
|
|
— |
|
|
|
|
— |
|
|
|
|
— |
|
|
|
|
— |
|
|
|
|
— |
|
|
Dividends paid to stockholders |
|
|
— |
|
|
|
|
— |
|
|
|
|
— |
|
|
|
|
— |
|
|
|
|
( |
) |
|
|
|
( |
) |
|
Balances at September 30, 2022 |
|
|
|
|
$ |
|
|
|
$ |
|
( |
) |
|
$ |
|
|
|
$ |
|
( |
) |
|
$ |
|
|
|
|
|
Common Stock |
|
|
|
|
|
|
Paid-in Capital |
|
|
Accumulated |
|
|
|
|
|
||||||||||||
For the Nine Months Ended September 30, 2022 |
|
Shares (1) |
|
|
Amount |
|
|
Treasury Stock |
|
|
in Excess of Par Value |
|
|
Undistributed Earnings (Losses) |
|
|
Total Net Assets |
|
||||||||||||
Balances at December 31, 2021 |
|
|
|
|
$ |
|
|
|
$ |
|
— |
|
|
$ |
|
|
|
$ |
|
( |
) |
|
$ |
|
|
|||||
Net increase (decrease) in net assets resulting from operations |
|
|
— |
|
|
|
|
— |
|
|
|
|
— |
|
|
|
|
— |
|
|
|
|
|
|
|
|
|
|||
Issuance of common stock |
|
|
— |
|
|
|
|
— |
|
|
|
|
— |
|
|
|
|
— |
|
|
|
|
— |
|
|
|
|
— |
|
|
Acquisition of treasury shares |
|
|
( |
) |
|
|
|
— |
|
|
|
|
( |
) |
|
|
|
— |
|
|
|
|
— |
|
|
|
|
( |
) |
|
Refunds (payments) of offering costs |
|
|
— |
|
|
|
|
— |
|
|
|
|
— |
|
|
|
|
|
|
|
|
— |
|
|
|
|
|
|||
Dividends paid to stockholders |
|
|
— |
|
|
|
|
— |
|
|
|
|
— |
|
|
|
|
— |
|
|
|
|
( |
) |
|
|
|
( |
) |
|
Balances at September 30, 2022 |
|
|
|
|
$ |
|
|
|
$ |
|
( |
) |
|
$ |
|
|
|
$ |
|
( |
) |
|
$ |
|
|
(1) |
Number of shares is shown net of cumulative treasury stock repurchases of |
See notes to financial statements.
3
RUNWAY GROWTH FINANCE CORP.
Statements of Cash Flows
(Unaudited)
(In thousands)
|
|
For the Nine Months Ended September 30, |
|
|||||||
|
|
2023 |
|
|
2022 |
|
||||
Cash flows from operating activities |
|
|
|
|
|
|
|
|
||
Net increase in net assets resulting from operations |
|
$ |
|
|
|
$ |
|
|
||
Adjustments to reconcile net increase in net assets resulting from operations to net cash provided by (used in) operating activities: |
|
|
|
|
|
|
|
|
||
Purchases of investments |
|
|
|
( |
) |
|
|
|
( |
) |
Purchases of U.S. Treasury Bills |
|
|
|
( |
) |
|
|
|
— |
|
Payment-in-kind interest |
|
|
|
( |
) |
|
|
|
( |
) |
Sales or repayments of investments |
|
|
|
|
|
|
|
|
||
Sales or maturities of U.S. Treasury Bills |
|
|
|
|
|
|
|
|
||
Net realized (gain) loss on investments |
|
|
|
|
|
|
|
( |
) |
|
Net change in unrealized (gain) loss on investments |
|
|
|
|
|
|
|
|
||
Amortization of fixed income premiums or accretion of discounts |
|
|
|
( |
) |
|
|
|
( |
) |
Amortization of deferred debt costs |
|
|
|
|
|
|
|
|
||
Changes in operating assets and liabilities: |
|
|
|
|
|
|
|
|
||
(Increase) decrease in interest and fees receivable |
|
|
|
|
|
|
|
( |
) |
|
(Increase) decrease in other assets |
|
|
|
|
|
|
|
|
||
Increase (decrease) in incentive fees payable |
|
|
|
|
|
|
|
|
||
Increase (decrease) in interest payable |
|
|
|
|
|
|
|
|
||
Increase (decrease) in accrued expenses and other liabilities |
|
|
|
|
|
|
|
|
||
Net cash provided by (used in) operating activities |
|
|
|
|
|
|
|
( |
) |
|
Cash flows from financing activities |
|
|
|
|
|
|
|
|
||
Payments of deferred debt costs |
|
|
|
( |
) |
|
|
|
( |
) |
Borrowings under credit facility |
|
|
|
|
|
|
|
|
||
Repayments under credit facility |
|
|
|
( |
) |
|
|
|
( |
) |
Proceeds from 2026 Notes |
|
|
|
|
|
|
|
|
||
Proceeds from 2027 Notes |
|
|
|
— |
|
|
|
|
|
|
Repayments of reverse repurchase agreements |
|
|
|
— |
|
|
|
|
( |
) |
Acquisition of treasury shares |
|
|
|
— |
|
|
|
|
( |
) |
Dividends paid to stockholders |
|
|
|
( |
) |
|
|
|
( |
) |
Refunds (payments) of offering costs |
|
|
|
— |
|
|
|
|
|
|
Net cash (used in) provided by financing activities |
|
|
|
( |
) |
|
|
|
|
|
Net increase (decrease) in cash |
|
|
|
|
|
|
|
|
||
Cash and cash equivalents at beginning of period |
|
|
|
|
|
|
|
|
||
Cash and cash equivalents at end of period |
|
$ |
|
|
|
$ |
|
|
||
Supplemental and non-cash financing cash flow information: |
|
|
|
|
|
|
|
|
||
Taxes paid |
|
$ |
|
|
|
$ |
|
|
||
Interest paid |
|
|
|
|
|
|
|
|
||
Non-cash portfolio purchases |
|
|
|
|
|
|
|
|
See notes to financial statements.
4
RUNWAY GROWTH FINANCE CORP.
Schedule of Investments (Unaudited)
September 30, 2023
(In thousands, except share and per share data)
Portfolio Company |
|
Investment |
|
Initial Acquisition Date |
|
Maturity Date |
|
Principal ($) / Shares |
|
|
Cost ($) |
|
|
Fair |
|
|
Footnotes |
||||||||
Non-Control/Non-Affiliate Investments |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
|
Senior Secured Term Loans |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
|
Application Software |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
Circadence Corporation |
|
SOFR+ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(9) (10) |
|||||
|
|
FiscalNote, Inc. |
|
PRIME+ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(9) (10) (11) (13) |
|||||
|
|
VTX Intermediate Holdings, Inc. (dba VertexOne) |
|
SOFR+ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(9) (10) (11) |
|||||
|
|
Total Application Software - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
|
Data Processing & Outsourced Services |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
Elevate Services, Inc. |
|
SOFR+ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(11) |
|||||
|
|
Interactions Corporation |
|
SOFR+ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(10) (11) |
|||||
|
|
ShareThis, Inc. |
|
SOFR+ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(10) (11) |
|||||
|
|
|
|
SOFR+ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(10) (11) |
|||||
|
|
Vesta Payment Solutions, Inc. |
|
SOFR+ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(10) (11) |
|||||
|
|
Total Data Processing & Outsourced Services - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
|
Education Services |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
Turning Tech Intermediate, Inc. (dba Echo 360, Inc.) |
|
SOFR+ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(9) (10) (11) |
|||||
|
|
Total Education Services - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
|
Electronic Equipment & Instruments |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
Brivo, Inc. |
|
SOFR+ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(10) (11) |
|||||
|
|
Total Electronic Equipment & Instruments - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
See notes to financial statements.
5
RUNWAY GROWTH FINANCE CORP.
Schedule of Investments (Unaudited) – (continued)
September 30, 2023
(In thousands, except share and per share data)
Portfolio Company |
|
Investment |
|
Initial Acquisition Date |
|
Maturity Date |
|
Principal ($) / Shares |
|
|
Cost ($) |
|
|
Fair |
|
|
Footnotes |
||||||||
Non-Control/Non-Affiliate Investments |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
|
Senior Secured Term Loans |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
|
Health Care Equipment |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
Moximed, Inc. |
|
PRIME+ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(10) (11) |
|||||
|
|
Total Health Care Equipment - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
|
Health Care Technology |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
EBR Systems, Inc. |
|
PRIME+ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(10) (11) (15) |
|||||
|
|
Mingle Healthcare Solutions, Inc. |
|
SOFR+ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(9) (10) |
|||||
|
|
Nalu Medical, Inc. |
|
PRIME+ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(9) (10) (11) |
|||||
|
|
Route 92 Medical, Inc. |
|
SOFR+ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(10) (11) |
|||||
|
|
SetPoint Medical Corporation |
|
SOFR+ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(10) (11) |
|||||
|
|
VERO Biotech LLC |
|
SOFR+ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(10) (11) |
|||||
|
|
Total Health Care Technology - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
|
Human Resource & Employment Services |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
CloudPay, Inc. |
|
PRIME+ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(7) (8) (10) (11) |
|||||
|
|
Snagajob.com, Inc. |
|
SOFR+ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(9) (10) |
|||||
|
|
Total Human Resource & Employment Services - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
|
Internet & Direct Marketing Retail |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
Madison Reed, Inc. |
|
PRIME+ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(9) (10) (11) |
|||||
|
|
Marley Spoon SE |
|
SOFR+ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(6) (8) (9) (11) |
|||||
|
|
Total Internet & Direct Marketing Retail - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
See notes to financial statements.
6
RUNWAY GROWTH FINANCE CORP.
Schedule of Investments (Unaudited) – (continued)
September 30, 2023
(In thousands, except share and per share data)
Portfolio Company |
|
Investment |
|
Initial Acquisition Date |
|
Maturity Date |
|
|
Principal ($) / Shares |
|
|
Cost ($) |
|
|
Fair |
|
|
Footnotes |
|||||||||
Non-Control/Non-Affiliate Investments |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
Senior Secured Term Loans |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
|
|
Internet Software and Services |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
|
Bombora, Inc. |
|
SOFR+ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(9) (10) (11) |
||||||
|
|
Skillshare, Inc. |
|
SOFR+ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(10) (11) |
||||||
|
|
Synack, Inc. |
|
PRIME+ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(11) |
||||||
|
|
Total Internet Software and Services - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
|
Property & Casualty Insurance |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
|
Kin Insurance, Inc. |
|
PRIME+ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(10) (11) |
||||||
|
|
Total Property & Casualty Insurance - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
|
System Software |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
|
3PL Central LLC (dba Extensiv) |
|
SOFR+ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(9) (10) (11) |
||||||
|
|
Total System Software - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Total Senior Secured Term Loans - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Second Lien Term Loans |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
|
|
System Software |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
|
Dejero Labs Inc. |
|
SOFR+ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(5) (8) (9) (10) (11) |
||||||
|
|
Total System Software - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Total Second Lien Term Loans - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Preferred Stocks |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
|
|
Application Software |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
|
Aria Systems, Inc. |
|
Series G Preferred Stock |
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(12) |
||||
|
|
Total Application Software - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
|
Health Care Technology |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
|
CareCloud, Inc. |
|
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(14) (16) |
|||||
|
|
Total Health Care Technology - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Total Preferred Stocks - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
See notes to financial statements.
7
RUNWAY GROWTH FINANCE CORP.
Schedule of Investments (Unaudited) – (continued)
September 30, 2023
(In thousands, except share and per share data)
Portfolio Company |
|
Investment |
|
Initial Acquisition Date |
|
Maturity Date |
|
|
Principal ($) / Shares |
|
|
Cost ($) |
|
|
Fair |
|
|
Footnotes |
|||||||||
Non-Control/Non-Affiliate Investments |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
Common Stocks |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
|
|
Application Software |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
|
FiscalNote, Inc. |
|
Common Stock |
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(12) (13) (16) |
||||
|
|
Total Application Software - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
|
Internet & Direct Marketing Retail |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
|
Marley Spoon SE |
|
Common Stock |
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(6) (12) (19) |
||||
|
|
Total Internet & Direct Marketing Retail - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
|
Technology Hardware, Storage & Peripherals |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
|
Quantum Corporation |
|
Common Stock |
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(8) (12) (14) (16) |
||||
|
|
zSpace, Inc. |
|
Common Stock |
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
|
— |
|
|
(12) |
|||
|
|
Total Technology Hardware, Storage & Peripherals - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Total Common Stocks - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Warrants |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
|
|
Advertising |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
|
STN Video Inc. |
|
Class B Non-Voting Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
— |
|
|
(5) (8) (12) |
|||||
|
|
Total Advertising - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
— |
|
|
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
|
Application Software |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
|
3DNA Corp. (dba NationBuilder) |
|
Series C-1 Preferred Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
— |
|
|
(12) |
|||||
|
|
Aria Systems, Inc. |
|
Series G Preferred Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(12) |
||||||
|
|
Circadence Corporation |
|
Series A-6 Preferred Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(12) |
||||||
|
|
|
|
Series A-6 Preferred Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(12) |
||||||
|
|
Dtex Systems, Inc. |
|
Series C-Prime Preferred Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(12) |
||||||
|
|
|
|
Series C-Prime Preferred Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(12) |
||||||
|
|
FiscalNote, Inc. |
|
Earnout |
|
|
|
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
(12) (13) (18) |
|||||
|
|
Porch Group, Inc. |
|
Earnout |
|
|
|
|
|
|
— |
|
|
|
|
— |
|
|
|
|
— |
|
|
(12) (14) (18) |
|||
|
|
Total Application Software - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
|
Biotechnology |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
|
Mustang Bio, Inc. |
|
Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(12) (14) |
||||||
|
|
TRACON Pharmaceuticals, Inc. |
|
Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(12) (14) |
||||||
|
|
Total Biotechnology - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
|
Computer & Electronics Retail |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
|
Massdrop, Inc. |
|
Series B Preferred Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
— |
|
|
(12) |
|||||
|
|
Total Computer & Electronics Retail - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
— |
|
|
|
See notes to financial statements.
8
RUNWAY GROWTH FINANCE CORP.
Schedule of Investments (Unaudited) – (continued)
September 30, 2023
(In thousands, except share and per share data)
Portfolio Company |
|
Investment |
|
Initial Acquisition Date |
|
Maturity Date |
|
Principal ($) / Shares |
|
|
Cost ($) |
|
|
Fair |
|
|
Footnotes |
||||||||
Non-Control/Non-Affiliate Investments |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
|
Warrants |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
|
Data Processing & Outsourced Services |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
Elevate Services, Inc. |
|
Series C Preferred Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(12) |
|||||
|
|
Interactions Corporation |
|
Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(12) |
|||||
|
|
ShareThis, Inc. |
|
Series D-3 Preferred Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(12) |
|||||
|
|
Total Data Processing & Outsourced Services - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
|
Electronic Equipment & Instruments |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
Brivo, Inc. |
|
Series A-2 Preferred Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(12) |
|||||
|
|
Epic IO Technologies, Inc. |
|
Success fee |
|
|
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
(12) (18) |
||||
|
|
Total Electronic Equipment & Instruments - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
|
Health Care Equipment |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
Moximed, Inc. |
|
Series C Preferred Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(12) |
|||||
|
|
Revelle Aesthetics, Inc. |
|
Series A-2 Preferred Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(12) |
|||||
|
|
Total Health Care Equipment - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
|
Health Care Technology |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
Allurion Technologies, Inc. |
|
Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(12) (13) |
|||||
|
|
|
|
Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(12) (13) |
|||||
|
|
|
|
Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(12) (13) |
|||||
|
|
|
|
Earnout |
|
|
|
|
|
— |
|
|
|
|
— |
|
|
|
|
|
|
(12) (13) (18) |
|||
|
|
EBR Systems, Inc. |
|
Success fee |
|
|
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
(12) (15) (18) |
||||
|
|
Mingle Healthcare Solutions, Inc. |
|
Series CC Preferred Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
— |
|
|
(12) |
||||
|
|
Nalu Medical, Inc. |
|
Series D-2 Preferred Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(12) |
|||||
|
|
Route 92 Medical, Inc. |
|
Success fee |
|
|
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
(12) (18) |
||||
|
|
SetPoint Medical Corporation |
|
Series B' Preferred Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(12) |
|||||
|
|
|
|
Series B' Preferred Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(12) |
|||||
|
|
VERO Biotech LLC |
|
Success fee |
|
|
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
(12) (18) |
||||
|
|
Total Health Care Technology - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
|
Human Resource & Employment Services |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
CloudPay, Inc. |
|
Series B Preferred Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(7) (8) (12) |
|||||
|
|
|
|
Series D Preferred Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(7) (8) (12) |
|||||
|
|
|
|
Series D Preferred Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(7) (8) (12) |
|||||
|
|
Snagajob.com, Inc. |
|
Series B-1 Preferred Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
— |
|
|
(12) |
||||
|
|
Total Human Resource & Employment Services - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
See notes to financial statements.
9
RUNWAY GROWTH FINANCE CORP.
Schedule of Investments (Unaudited) – (continued)
September 30, 2023
(In thousands, except share and per share data)
Portfolio Company |
|
Investment |
|
Initial Acquisition Date |
|
Maturity Date |
|
Principal ($) / Shares |
|
|
Cost ($) |
|
|
Fair |
|
|
Footnotes |
||||||||
Non-Control/Non-Affiliate Investments |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
|
Warrants |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
|
Internet & Direct Marketing Retail |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
Madison Reed, Inc. |
|
Success fee |
|
|
N/A |
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
(12) (18) |
|||
|
|
Total Internet & Direct Marketing Retail - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
|
Internet Software and Services |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
Bombora, Inc. |
|
Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(12) |
|||||
|
|
Fidelis Cybersecurity, Inc. |
|
Common Stock |
|
|
|
|
|
— |
|
|
|
|
|
|
|
|
— |
|
|
(12) (17) |
|||
|
|
INRIX, Inc. |
|
Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(12) |
|||||
|
|
Longtail Ad Solutions, Inc. (dba JW Player) |
|
Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(12) |
|||||
|
|
Skillshare, Inc. |
|
Success fee |
|
|
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
(12) (18) |
||||
|
|
Synack, Inc. |
|
Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(12) |
|||||
|
|
Total Internet Software and Services - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
|
Property & Casualty Insurance |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
Kin Insurance, Inc. |
|
Series D-3 Preferred Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(12) |
|||||
|
|
|
|
Series D-3 Preferred Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
— |
|
|
(12) |
||||
|
|
|
|
Series D-3 Preferred Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
— |
|
|
(12) |
||||
|
|
Total Property & Casualty Insurance - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
|
Specialized Consumer Services |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
AllClear ID, Inc. |
|
Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
— |
|
|
(12) |
||||
|
|
|
|
Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
— |
|
|
(12) |
||||
|
|
Credit Sesame, Inc. |
|
Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(12) |
|||||
|
|
Total Specialized Consumer Services - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
|
System Software |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
Dejero Labs Inc. |
|
Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(5) (8) (12) |
|||||
|
|
Scale Computing, Inc. |
|
Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
— |
|
|
(12) |
||||
|
|
Total System Software - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
|
Technology Hardware, Storage & Peripherals |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
RealWear, Inc. |
|
Series A Preferred Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(12) |
|||||
|
|
|
|
Series A Preferred Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(12) |
|||||
|
|
|
|
Series A Preferred Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(12) |
|||||
|
|
Total Technology Hardware, Storage & Peripherals - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
Total Warrants - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Total Non-Control/Non-Affiliate Investments - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
See notes to financial statements.
10
RUNWAY GROWTH FINANCE CORP.
Schedule of Investments (Unaudited) – (continued)
September 30, 2023
(In thousands, except share and per share data)
Portfolio Company |
|
Investment |
|
Initial Acquisition Date |
|
Maturity Date |
|
|
Principal ($) / Shares |
|
|
Cost ($) |
|
|
Fair |
|
|
Footnotes |
|||||||||
Affiliate Investments |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(20) |
||||||||
|
Senior Secured Term Loans |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
|
|
Health Care Technology |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
|
Gynesonics, Inc. |
|
SOFR+ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(10) (11) |
||||||
|
|
Total Health Care Technology - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Total Senior Secured Term Loans - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Preferred Stocks |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
|
|
Health Care Technology |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
|
Gynesonics, Inc. |
|
Series A-2 Preferred Stock |
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(12) |
||||
|
|
Total Health Care Technology - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Total Preferred Stocks - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Common Stocks |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
|
|
Application Software |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
|
Coginiti Corp |
|
Common Stock |
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(12) |
||||
|
|
Total Application Software - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Total Common Stocks - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Warrants |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
|
|
Application Software |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
|
Coginiti Corp |
|
Common Stock |
|
|
|
|
|
|
|
|
|
|
— |
|
|
|
|
|
|
(12) |
|||||
|
|
Total Application Software - |
|
|
|
|
|
|
|
|
|
|
|
|
— |
|
|
|
|
|
|
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
|
Health Care Technology |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
|
Gynesonics, Inc. |
|
Success fee |
|
|
|
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
(12) (18) |
|||||
|
|
Total Health Care Technology - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Total Warrants - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
Total Affiliate Investments - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
Control Investments |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(21) |
||||||||
|
Senior Secured Term Loans |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
|
|
Data Processing & Outsourced Services |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
|
Pivot3, Inc. |
|
LIBOR+ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(9) (10) (12) |
||||||
|
|
Total Data Processing & Outsourced Services - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Total Senior Secured Term Loans - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
Total Control Investments - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
Total Investments - |
|
|
|
|
|
|
|
|
|
|
$ |
|
|
|
$ |
|
|
|
|
See notes to financial statements.
11
RUNWAY GROWTH FINANCE CORP.
Schedule of Investments (Unaudited) – (continued)
September 30, 2023
(1) |
|
Disclosures of interest rates on notes include cash interest rates and payment-in-kind ("PIK") interest rates, as applicable. Unless otherwise indicated, all of the Company's variable interest rate debt instruments bear interest at a rate that is determined by reference to the 3-Month London Interbank Offered Rate ("LIBOR"), the U.S. Prime Rate, or the 3-month Secured Overnight Financing Rate ("SOFR"). At September 30, 2023, the 3-Month LIBOR was |
(2) |
|
The Company’s investments are generally acquired in private transactions exempt from registration under the Securities Act of 1933, as amended (the “Securities Act”), and, therefore, except as otherwise noted, are subject to limitation on resale, may be deemed to be “restricted securities” under the Securities Act, and were valued at fair value as determined in good faith by the Company’s Board of Directors. |
(3) |
|
Investments are held at Fair Value net of the Fair Value of Unfunded Commitments. Refer to "Note 8 – Commitments and Contingencies" for additional detail. |
(4) |
|
All portfolio companies are domiciled in the United States, unless otherwise noted. |
(5) |
|
Portfolio company is domiciled in Canada. |
(6) |
|
Portfolio company is domiciled in Germany |
(7) |
|
Portfolio company is domiciled in United Kingdom. |
(8) |
|
Investment is not a qualifying investment as defined under Section 55(a) of the Investment Company Act of 1940, as amended. The fair value of non-qualifying assets represent |
(9) |
|
Represents a PIK security. PIK interest will be accrued and paid at maturity. |
(10) |
|
Disclosures of end-of-term payments ("ETP") are one-time payments stated as a percentage of original principal amount. |
(11) |
|
The investment is an eligible loan investment in the collateral under the Credit Facility (as defined in "Note 7 – Borrowings"). |
(12) |
|
Investments are non-income producing. |
(13) |
|
Portfolio company is publicly traded and listed on NYSE. |
(14) |
|
Portfolio company is publicly traded and listed on NASDAQ. |
(15) |
|
Portfolio company is publicly traded and listed on ASX. |
(16) |
|
Investment is not a "restricted security" under the Securities Act. |
(17) |
|
The warrant count is based upon a percentage of ownership of Fidelis Cybersecurity, Inc. |
(18) |
|
Investment is either a cash success fee payable or earnout of shares based on the consummation of certain trigger events. |
(19) |
|
Investment is denominated in a foreign currency and is publicly traded on ETR. At each balance sheet date, portfolio company investments denominated in foreign currencies are translated into U.S. dollars using the spot exchange rate on the last business day of the period. Transactions of foreign portfolio company investments, and income related from such investments, are translated into U.S. dollars using relevant rates of exchange on the respective dates of such transactions. |
(20) |
|
Affiliate portfolio company as defined under the 1940 Act in which the Company owns between |
(21) |
|
Control portfolio company, as defined under the 1940 Act, in which the Company owns more than |
* |
|
Value as a percentage of net assets. |
See notes to financial statements.
12
RUNWAY GROWTH FINANCE CORP.
Schedule of Investments
December 31, 2022
(In thousands, except share and per share data)
Portfolio Company |
|
Investment |
|
Initial Acquisition Date |
|
Maturity Date |
|
Principal ($) / Shares |
|
|
Cost ($) |
|
|
Fair |
|
|
Footnotes |
||||||||
Non-Control/Non-Affiliate Investments |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
|
Senior Secured Term Loans |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
|
Application Software |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
Circadence Corporation |
|
SOFR+ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(4)(8) |
|||||
|
|
Dtex Systems, Inc. |
|
SOFR+ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(8) |
|||||
|
|
FiscalNote, Inc. |
|
PRIME+ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(4)(8) |
|||||
|
|
VTX Intermediate Holdings, Inc. (dba VertexOne) |
|
SOFR+ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(8) |
|||||
|
|
Total Application Software - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
|
Biotechnology |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
Mustang Bio, Inc. |
|
SOFR+ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(8) |
|||||
|
|
TRACON Pharmaceuticals, Inc. |
|
PRIME+ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(8) |
|||||
|
|
Total Biotechnology - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
|
Data Processing & Outsourced Services |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
Interactions Corporation |
|
SOFR+ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(8) |
|||||
|
|
ShareThis, Inc. |
|
SOFR+ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(8) |
|||||
|
|
|
|
SOFR+ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(8) |
|||||
|
|
Vesta Payment Solutions, Inc. |
|
SOFR+ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(8) |
|||||
|
|
Total Data Processing & Outsourced Services - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
|
Education Services |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
Turning Tech Intermediate, Inc. (dba Echo 360, Inc.) |
|
SOFR+ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(4)(8) |
|||||
|
|
Total Education Services - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
|
Electronic Equipment & Instruments |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
Brivo, Inc. |
|
SOFR+ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(4)(8) |
|||||
|
|
Intellisite Holdings, Inc. (dba Epic IO Technologies, Inc.) |
|
SOFR+ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
Total Electronic Equipment & Instruments - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
See notes to financial statements.
13
RUNWAY GROWTH FINANCE CORP.
Schedule of Investments – (continued)
December 31, 2022
(In thousands, except share and per share data)
Portfolio Company |
|
Investment |
|
Initial Acquisition Date |
|
Maturity Date |
|
Principal ($) / Shares |
|
|
Cost ($) |
|
|
Fair |
|
|
Footnotes |
||||||||
Non-Control/Non-Affiliate Investments |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
|
Senior Secured Term Loans |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
|
Health Care Equipment |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
Moximed, Inc. |
|
PRIME+ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(8) |
|||||
|
|
Revelle Aesthetics, Inc. |
|
PRIME+ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(8) |
|||||
|
|
Total Health Care Equipment - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
|
Health Care Technology |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
Allurion Technologies, Inc. |
|
PRIME+ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(8) |
|||||
|
|
EBR Systems, Inc. |
|
PRIME+ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(8)(20) |
|||||
|
|
Gynesonics, Inc. |
|
SOFR+ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(8) |
|||||
|
|
Mingle Healthcare Solutions, Inc. |
|
SOFR+ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(4)(8) |
|||||
|
|
Nalu Medical, Inc. |
|
PRIME+ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(4)(8) |
|||||
|
|
Route 92 Medical, Inc. |
|
SOFR+ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(8) |
|||||
|
|
SetPoint Medical Corporation |
|
SOFR+ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(8) |
|||||
|
|
VERO Biotech LLC |
|
SOFR+ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(8) |
|||||
|
|
Total Health Care Technology - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
|
Human Resource & Employment Services |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
CloudPay, Inc. |
|
PRIME+ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(3)(8)(12) |
|||||
|
|
Snagajob.com, Inc. |
|
SOFR+ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(4)(8) |
|||||
|
|
Total Human Resource & Employment Services - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
|
Internet & Direct Marketing Retail |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
Madison Reed, Inc. |
|
PRIME+ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(8) |
|||||
|
|
Marley Spoon AG |
|
SOFR+ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(3)(4)(8)(11) |
|||||
|
|
Total Internet & Direct Marketing Retail - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
See notes to financial statements.
14
RUNWAY GROWTH FINANCE CORP.
Schedule of Investments – (continued)
December 31, 2022
(In thousands, except share and per share data)
Portfolio Company |
|
Investment |
|
Initial Acquisition Date |
|
Maturity Date |
|
Principal ($) / Shares |
|
|
Cost ($) |
|
|
Fair |
|
|
Footnotes |
||||||||
Non-Control/Non-Affiliate Investments |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
|
Senior Secured Term Loans |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
|
Internet Software and Services |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
Bombora, Inc. |
|
SOFR+ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(4)(8) |
|||||
|
|
Fidelis Cybersecurity, Inc. |
|
SOFR+ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(8) |
|||||
|
|
|
|
SOFR+ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(8) |
|||||
|
|
INRIX, Inc. |
|
SOFR+ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(8) |
|||||
|
|
Skillshare, Inc. |
|
SOFR+ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(8) |
|||||
|
|
Synack, Inc. |
|
PRIME+ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(8) |
|||||
|
|
Total Internet Software and Services - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
|
Property & Casualty Insurance |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
Kin Insurance, Inc. |
|
PRIME+ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(8) |
|||||
|
|
Total Property & Casualty Insurance - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
|
System Software |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
3PL Central LLC |
|
SOFR+ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(4)(8) |
|||||
|
|
Total System Software - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
Total Senior Secured Term Loans - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
Second Lien Term Loans |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
|
System Software |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
Dejero Labs Inc. |
|
SOFR+ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(3)(4)(8)(10) |
|||||
|
|
Total System Software - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
Total Second Lien Term Loans - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
Preferred Stocks |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
|
Application Software |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
Aria Systems, Inc. |
|
Series G |
|
|
N/A |
|
|
|
|
|
|
|
|
|
|
|
|
|
(7) |
||||
|
|
Total Application Software - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
|
Health Care Technology |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
CareCloud, Inc. |
|
|
|
N/A |
|
|
|
|
|
|
|
|
|
|
|
|
|
(15)(17) |
|||||
|
|
Total Health Care Technology - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
Total Preferred Stocks - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
See notes to financial statements.
15
RUNWAY GROWTH FINANCE CORP.
Schedule of Investments – (continued)
December 31, 2022
(In thousands, except share and per share data)
Portfolio Company |
|
Investment |
|
Initial Acquisition Date |
|
Maturity Date |
|
Principal ($) / Shares |
|
|
Cost ($) |
|
|
Fair |
|
|
Footnotes |
||||||||
Non-Control/Non-Affiliate Investments |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
|
Common Stocks |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
|
Application Software |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
FiscalNote, Inc. |
|
|
|
|
N/A |
|
|
|
|
|
|
|
|
|
|
|
|
|
(7)(19) |
||||
|
|
Total Application Software - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
|
Technology Hardware, Storage & Peripherals |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
Quantum Corporation |
|
|
|
|
N/A |
|
|
|
|
|
|
|
|
|
|
|
|
|
(3)(7)(15)(17) |
||||
|
|
zSpace, Inc. |
|
|
|
|
N/A |
|
|
|
|
|
|
|
|
|
|
|
- |
|
|
(7) |
|||
|
|
Total Technology Hardware, Storage & Peripherals - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
Total Common Stocks - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
Warrants |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
|
Advertising |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
STN Video Inc. |
|
Class B Non-Voting Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
— |
|
|
(3)(7) |
||||
|
|
Total Advertising - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
— |
|
|
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
|
Application Software |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
3DNA Corp. (dba NationBuilder) |
|
Series C-1 Preferred Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
— |
|
|
(7) |
||||
|
|
Aria Systems, Inc. |
|
Series G Preferred Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(7) |
|||||
|
|
Circadence Corporation |
|
Series A-6 Preferred Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(7) |
|||||
|
|
|
|
Series A-6 Preferred Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(7) |
|||||
|
|
Dtex Systems, Inc. |
|
Series C-Prime Preferred Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(7) |
|||||
|
|
|
|
Series C-Prime Preferred Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(7) |
|||||
|
|
FiscalNote, Inc. |
|
Earnout |
|
|
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
(7)(13)(19) |
||||
|
|
Porch Group, Inc. |
|
Earnout |
|
|
|
|
|
— |
|
|
|
|
— |
|
|
|
|
— |
|
|
(7)(13)(15) |
||
|
|
Total Application Software - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
|
Biotechnology |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
Mustang Bio, Inc. |
|
Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(7) |
|||||
|
|
TRACON Pharmaceuticals, Inc. |
|
Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(7)(15) |
|||||
|
|
Total Biotechnology - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
|
Computer & Electronics Retail |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
Massdrop, Inc. |
|
Series B Preferred Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(7) |
|||||
|
|
Total Computer & Electronics Retail - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
See notes to financial statements.
16
RUNWAY GROWTH FINANCE CORP.
Schedule of Investments – (continued)
December 31, 2022
(In thousands, except share and per share data)
Portfolio Company |
|
Investment |
|
Initial Acquisition Date |
|
Maturity Date |
|
Principal ($) / Shares |
|
|
Cost ($) |
|
|
Fair |
|
|
Footnotes |
||||||||
Non-Control/Non-Affiliate Investments |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
|
Warrants |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
|
Data Processing & Outsourced Services |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
Interactions Corporation |
|
Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(7) |
|||||
|
|
ShareThis, Inc. |
|
Series D-3 Preferred Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(7) |
|||||
|
|
Total Data Processing & Outsourced Services - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
|
Electronic Equipment & Instruments |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
Brivo, Inc. |
|
Series A-2 Preferred Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(7) |
|||||
|
|
Epic IO Technologies, Inc. |
|
Success fee |
|
|
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
(7)(13) |
||||
|
|
Total Electronic Equipment & Instruments - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
|
Health Care Equipment |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
Moximed, Inc. |
|
Series C Preferred Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(7) |
|||||
|
|
Revelle Aesthetics, Inc. |
|
Series A-2 Preferred Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(7) |
|||||
|
|
Total Health Care Equipment - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
|
Health Care Technology |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
Allurion Technologies, Inc. |
|
Series C Preferred Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(7) |
|||||
|
|
|
|
Series D-1 Preferred Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(7) |
|||||
|
|
CareCloud, Inc. |
|
Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
— |
|
|
(7) |
||||
|
|
EBR Systems, Inc. |
|
Success fee |
|
|
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
(7)(13)(20) |
||||
|
|
Gynesonics, Inc. |
|
Series G Convertible Preferred Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(7) |
|||||
|
|
Mingle Healthcare Solutions, Inc. |
|
Series CC Preferred Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
— |
|
|
(7) |
||||
|
|
Nalu Medical, Inc. |
|
Series D-2 Preferred Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(7) |
|||||
|
|
Route 92 Medical, Inc. |
|
Success fee |
|
|
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
(7)(13) |
||||
|
|
SetPoint Medical Corporation |
|
Series B Preferred Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(7) |
|||||
|
|
|
|
Series B Preferred Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(7) |
|||||
|
|
VERO Biotech LLC |
|
Success fee |
|
|
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
(7)(13) |
||||
|
|
Total Health Care Technology - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
|
Human Resource & Employment Services |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
CloudPay, Inc. |
|
Series B Preferred Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(3)(7)(12) |
|||||
|
|
|
|
Series D Preferred Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(3)(7)(12) |
|||||
|
|
Snagajob.com, Inc. |
|
Series B-1 Preferred Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(7) |
|||||
|
|
Total Human Resource & Employment Services - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
See notes to financial statements.
17
RUNWAY GROWTH FINANCE CORP.
Schedule of Investments – (continued)
December 31, 2022
(In thousands, except share and per share data)
Portfolio Company |
|
Investment |
|
Initial Acquisition Date |
|
Maturity Date |
|
Principal ($) / Shares |
|
|
Cost ($) |
|
|
Fair |
|
|
Footnotes |
||||||||
Non-Control/Non-Affiliate Investments |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
|
Warrants |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
|
Internet & Direct Marketing Retail |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
Madison Reed, Inc. |
|
Success fee |
|
|
N/A |
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
(7)(13) |
|||
|
|
Total Internet & Direct Marketing Retail - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
|
Internet Software and Services |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
Bombora, Inc. |
|
Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(7) |
|||||
|
|
Fidelis Cybersecurity, Inc. |
|
Common Stock |
|
|
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
(7)(16) |
||||
|
|
INRIX, Inc. |
|
Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(7) |
|||||
|
|
Longtail Ad Solutions, Inc. (dba JW Player) |
|
Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(7) |
|||||
|
|
Skillshare, Inc. |
|
Success fee |
|
|
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
(7)(13) |
||||
|
|
Synack, Inc. |
|
Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(7) |
|||||
|
|
Total Internet Software and Services - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
|
Property & Casualty Insurance |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
Kin Insurance, Inc. |
|
Series D-3 Preferred Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(7) |
|||||
|
|
Total Property & Casualty Insurance - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
|
Specialized Consumer Services |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
AllClear ID, Inc. |
|
Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
— |
|
|
(7) |
||||
|
|
Credit Sesame, Inc. |
|
Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(7) |
|||||
|
|
Total Specialized Consumer Services - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
|
System Software |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
Dejero Labs Inc. |
|
Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(3)(7)(10) |
|||||
|
|
Scale Computing, Inc. |
|
Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
— |
|
|
(7) |
||||
|
|
Total System Software - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
|
Technology Hardware, Storage & Peripherals |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
RealWear, Inc. |
|
Series A Preferred Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(7) |
|||||
|
|
|
|
Series A Preferred Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(7) |
|||||
|
|
|
|
Series A Preferred Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(7) |
|||||
|
|
Total Technology Hardware, Storage & Peripherals - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
Total Warrants - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Total Non-Control/Non-Affiliate Investments - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
See notes to financial statements.
18
RUNWAY GROWTH FINANCE CORP.
Schedule of Investments – (continued)
December 31, 2022
Portfolio Company |
|
Investment |
|
Initial Acquisition Date |
|
Maturity Date |
|
Principal ($) / Shares |
|
|
Cost ($) |
|
|
Fair |
|
|
Footnotes |
||||||||
Affiliate Investments |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(18) |
|||||||
|
Common Stocks |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
|
Application Software |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
Coginiti Corp |
|
|
|
|
N/A |
|
|
|
|
|
|
|
|
|
|
|
|
|
(7) |
||||
|
|
Total Application Software - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
Total Common Stocks - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
Warrants |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
|
Application Software |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
Coginiti Corp |
|
Common Stock |
|
|
|
|
|
|
|
|
|
— |
|
|
|
|
|
|
(7) |
||||
|
|
Total Application Software - |
|
|
|
|
|
|
|
|
|
|
|
— |
|
|
|
|
|
|
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
Total Warrants - |
|
|
|
|
|
|
|
|
|
|
|
— |
|
|
|
|
|
|
|
|||||
Total Affiliate Investments - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
|
Control Investments |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(14) |
||||||
|
Senior Secured Term Loans |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
|
Data Processing & Outsourced Services |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
Pivot3, Inc. |
|
LIBOR+ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(4)(7) |
|||||
|
|
Total Data Processing & Outsourced Services - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
Total Senior Secured Term Loans - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Total Control Investments - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
Total Investments - |
|
|
|
|
|
|
|
|
|
|
|
$ |
|
|
|
$ |
|
|
|
|
(1) |
Disclosures of interest rates on notes include cash interest rates and payment-in-kind (“PIK”) interest rates, as applicable. Unless otherwise indicated, all of the Company’s variable interest rate debt instruments bear interest at a rate that is determined by reference to the 3‑Month London Interbank Offered Rate (“LIBOR”), the U.S. Prime Rate, or the 3-Month Secured Overnight Financing Rate ("SOFR"). At December 31, 2022, the 3‑Month LIBOR was |
|||||||||||||
(2) |
The Company’s investments are generally acquired in private transactions exempt from registration under the Securities Act of 1933, as amended (the “Securities Act”) and, therefore, except as otherwise noted, are subject to limitation on resale, may be deemed to be “restricted securities” under the Securities Act, and were valued at fair value as determined in good faith by the Company’s Board of Directors. |
|||||||||||||
(3) |
Investment is not a qualifying asset as defined under Section 55(a) of the Investment Company Act of 1940, as amended (the “1940 Act”). Non-qualifying assets at fair value represent |
|||||||||||||
(4) |
Represents a PIK security. PIK interest is accrued and will be paid at maturity. |
|||||||||||||
(5) |
Disclosures of end-of-term-payments (“ETP”) are one-time payments stated as a percentage of original principal amount. |
|||||||||||||
(6) |
Investments are held at Fair Value net of the Fair Value of Unfunded Commitments. Refer to "Note 8 – Commitments and Contingencies" for additional detail. |
|||||||||||||
(7) |
Investments are non-income producing. |
|||||||||||||
(8) |
The investment is an eligible loan investment in the collateral under the Credit Facility (as defined in "Note 7 – Borrowings"). |
|||||||||||||
(9) |
All portfolio companies are domiciled in the United States, unless otherwise noted. |
|||||||||||||
(10) |
Portfolio company is domiciled in Canada. |
|||||||||||||
(11) |
Portfolio company is domiciled in Germany |
|||||||||||||
(12) |
Portfolio company is domiciled in United Kingdom. |
|||||||||||||
(13) |
Investment is either a cash success fee payable or earnout of shares based on the consummation of certain trigger events. |
|||||||||||||
(14) |
Control portfolio company, as defined under the 1940 Act, in which the Company owns more than |
|||||||||||||
(15) |
Portfolio company is publicly traded and listed on NASDAQ. |
|||||||||||||
(16) |
The warrant count is based upon a percentage of ownership of Fidelis Cybersecurity, Inc. |
|||||||||||||
(17) |
Investment is not a "restricted security" under the Securities Act. |
|||||||||||||
(18) |
Affiliate portfolio company as defined under the 1940 Act in which the Company owns between |
|||||||||||||
(19) |
Portfolio company is publicly traded and listed on NYSE. |
|||||||||||||
(20) |
Portfolio company is publicly traded and listed on ASX. |
|||||||||||||
|
* |
Value as a percentage of net assets. |
|
|
|
|
|
|
|
|
|
|
|
|
See notes to financial statements.
19
RUNWAY GROWTH FINANCE CORP.
Notes to Financial Statements
(Unaudited)
Note 1 – Organization
Runway Growth Finance Corp. (formerly known as Runway Growth Credit Fund Inc.) (the “Company”), is a Maryland corporation that was formed on August 31, 2015. On August 18, 2021, the Company changed its name to “Runway Growth Finance Corp.” from “Runway Growth Credit Fund Inc.” The Company is an externally managed, non-diversified, closed-end investment company that has elected to be regulated as a business development company (“BDC”) under the Investment Company Act of 1940, as amended (the “1940 Act”). In addition, the Company has elected to be treated, currently qualifies, and intends to continue to qualify annually as a regulated investment company (“RIC”) under Subchapter M of the Internal Revenue Code of 1986, as amended (the “Code”).
The Company was formed primarily to lend to, and selectively invest in, high growth-potential companies in technology, life sciences, healthcare information and services, business services, select consumer services and products in other high-growth industries in the United States. The Company’s investment objective is to maximize its total return to its stockholders primarily through current income on its loan portfolio, and secondarily through capital appreciation on its warrants and other equity positions. The Company’s investment activities are managed by its external investment adviser, Runway Growth Capital LLC (“RGC”). The Company’s administrator, Runway Administrator Services LLC (the “Administrator”), is a wholly owned subsidiary of RGC and provides administrative services necessary for the Company to operate.
On October 25, 2021, the Company closed its initial public offering ("IPO"), issuing
Note 2 – Summary of Significant Accounting Policies
Basis of Presentation
The accompanying interim unaudited financial statements of the Company are prepared on the accrual basis of accounting in conformity with U.S. Generally Accepted Accounting Principles (“U.S. GAAP”) and pursuant to the requirements for reporting on Form 10‑Q and Regulation S-X under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The Company is an investment company following the specialized accounting and reporting guidance specified in the Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) Topic 946, Financial Services — Investment Companies.
In the opinion of management, all adjustments, all of which were of a normal recurring nature, considered necessary for the fair presentation of financial statements for the interim period have been included. The results of operations for the current interim period are not necessarily indicative of results that ultimately may be achieved for any other interim period or for the year ending December 31, 2023. The interim unaudited financial statements and notes hereto should be read in conjunction with the audited financial statements and notes thereto contained in the Company’s annual report on Form 10-K for the year ended December 31, 2022, filed with the Securities and Exchange Commission (the "SEC") on March 2, 2023.
Certain items in the September 30, 2022 and December 31, 2022 financial statements have been reclassified to conform to the September 30, 2023 presentation with no effect on the net assets on the Statements of Assets and Liabilities, and no net effect on the net increase in net assets resulting from operations on the Statements of Operations.
Use of Estimates
The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of income and expense during the reporting period. Actual results could differ from those estimates.
20
Cash and Cash Equivalents
Cash consists solely of funds deposited with financial institutions, while cash equivalents consists of short-term liquid investments in money market funds. Cash and cash equivalents are carried at cost, which approximates fair value. As of September 30, 2023 and December 31, 2022, $
Debt and Deferred Debt Costs
The debt of the Company is carried at amortized cost, which is comprised of the principal amount borrowed, net of unamortized debt issuance costs on the Statements of Assets and Liabilities. Debt issuance costs are fees and other direct incremental costs incurred by the Company in relation to debt financing and are recognized as Unamortized deferred debt costs on the Statements of Assets and Liabilities and amortized over the life of the related debt instrument, or the life of the cost respective service if shorter, using the straight-line method, which closely approximates the effective yield method. To the extent there are no outstanding borrowings, the deferred debt costs are presented as an asset on the Statements of Assets and Liabilities.
Amortization of deferred debt costs and interest expense on the outstanding principal balance are recorded in Interest and other deferred financing expenses on the Statements of Operations. Accrued but unpaid interest is included within Interest payable on the Statements of Assets and Liabilities. For more information, refer to “Note 7 – Borrowings.”
Investment Transactions and Related Investment Income
Security transactions, if any, are recorded on a trade-date basis. Realized gains or losses from the repayment or sale of investments are measured using the specific identification method. The amortized cost basis of investments represents the original cost adjusted for the accretion/amortization of discounts and premiums and upfront loan origination fees. The Company reports changes from the prior period in fair value of investments that are measured at fair value as a component of net change in unrealized gain (loss) on investments on the Statements of Operations.
Dividends are recorded on the ex-dividend date. Interest income, if any, adjusted for amortization of market premium and accretion of market discount, is recorded on an accrual basis to the extent that the Company expects to collect such amounts. Original issue discount (“OID”), principally representing the estimated fair value of detachable equity, warrants or contractual success fees obtained in conjunction with the Company’s debt investments, loan origination fees, end of term payments, and market discount or premium are capitalized and accreted or amortized into interest income over the life of the respective security using the effective interest method. Loan origination fees received in connection with the closing of investments are reported as unearned income, which is included as amortized cost of the investment; the unearned income from such fees is accreted into interest income over the contractual life of the loan based on the effective interest method. Upon prepayment of a debt investment, any unamortized loan origination fees, end-of-term payments, and unamortized market discounts are recorded as interest income and any prepayment penalties are recorded as fee income. Upon amending terms of an existing investment, any amendment fees charged are recorded as fee income.
The Company currently holds, and expects to hold in the future, some investments in its portfolio that contain payment-in-kind (“PIK”) interest provisions. PIK interest is computed at the contractual rate specified in each loan agreement and is added to the principal balance of the loan, rather than being paid to the Company in cash, and is recorded as interest income. Thus, the actual collection of PIK interest may be deferred until the time of debt principal repayment. PIK interest, which is a non-cash source of income, is included in the Company’s taxable income and therefore affects the amount of income the Company is required to distribute to stockholders to maintain its qualification as a RIC for U.S. federal income tax purposes, even though the Company has not yet collected the cash. For the three and nine months ended September 30, 2023, approximately
21
Investments Denominated in Foreign Currency
At each balance sheet date, portfolio company investments denominated in foreign currencies are translated into U.S. dollars using the spot exchange rate on the last business day of the period. Purchases and sales of foreign portfolio company investments, and any income from such investments, are translated into U.S. dollars using the rates of exchange prevailing on the respective dates of such transactions. As of September 30, 2023, the Company held one investment denominated in a foreign currency. As of December 31, 2022, the Company did not hold any investments denominated in a foreign currency.
Although the fair values of foreign portfolio company investments and the fluctuation in such fair values are translated into U.S. dollars using the applicable foreign exchange rates described above, the Company does not isolate the portion of the change in fair value resulting from foreign currency exchange rates fluctuations from the change in fair value of the underlying investment. All fluctuations in fair value are included in Net change in unrealized gain (loss) on investments on the Company’s Statements of Operations.
Non-Accrual of Investments
Debt investments are placed on non-accrual status when principal, interest, and other obligations become materially past due or when there is reasonable doubt that principal, interest, or other obligations will be collected in full. At the point of non-accrual, the Company will cease recognizing interest income on the debt investment until all principal and interest due have been paid or the Company believes the borrower has demonstrated the ability to repay its current and future contractual obligations. Additionally, any OID associated with the debt investment is no longer accreted to interest income as of the date the loan is placed on non-accrual status. Any payments received on non-accrual loans are first applied to principal prior to recovery of any foregone interest or end of term payment fees. Non-accrual loans are restored to accrual status when past due principal or interest are paid, and, in management’s judgment are likely to remain current. The Company may make exceptions to this policy if the investment has sufficient collateral value and is in the process of collection such that the Company will be made whole on the investment, inclusive of interest and end of term payment fees.
As of September 30, 2023, and December 31, 2022, the Company has
22
Fair Value Measurements
The Company measures the value of its financial instruments at fair value in accordance with ASC Topic 820, Fair Value Measurements and Disclosure (“ASC Topic 820”), issued by the FASB. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. With the exception of the Company’s borrowings, which are reported at amortized cost, all assets and liabilities approximate fair value on the Statements of Assets and Liabilities.
ASC Topic 820 specifies a hierarchy of valuation techniques based on whether the inputs to those valuation techniques are observable or unobservable. ASC Topic 820 also provides guidance regarding a fair value hierarchy, which prioritizes information used to measure fair value and the effect of fair value measurements on earnings and provides for enhanced disclosures determined by the level within the hierarchy of information used in the valuation. In accordance with ASC Topic 820, these inputs are summarized in the three levels listed below:
In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, a financial instrument’s level within the fair value hierarchy is based on the lowest level of observable input that is significant to the fair value measurement. The assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the instrument.
Under ASC Topic 820, the fair value measurement also assumes that the transaction to sell an asset occurs in the principal market for the asset or, in the absence of a principal market, the most advantageous market for the asset, which may be a hypothetical market, and excludes transaction costs. The principal market for any asset or liability is the market with the greatest volume and level of activity for such asset or liability in which the reporting entity would or could sell or transfer the asset or liability. In determining the principal market for an asset or liability under ASC Topic 820, it is assumed that the reporting entity has access to such market as of the measurement date. Market participants are defined as buyers and sellers in the principal or most advantageous market that are independent, knowledgeable and willing and able to transact.
Rule 2a-5 under the 1940 Act established requirements for determining fair value of a BDC's investments in good faith for purposes of the 1940 Act. Rule 2a-5 permits boards, in compliance with certain conditions, to designate certain parties to perform fair value determinations, subject to board oversight. Rule 2a-5 also defines when market quotations are "readily available" for purposes of the 1940 Act and the threshold for determining whether a fund must determine the fair value of a security. The SEC also adopted new Rule 31a-4 under the 1940 Act ("Rule 31a-4"), which provides the recordkeeping requirements associated with fair value determinations. The Company's Board of Directors has not designated a valuation designee.
Investment Valuation Techniques
With respect to investments for which market quotations are not readily available, the Company undertakes a multi-step valuation process each quarter, as described below:
23
The Company’s investments are primarily loans made to and equity and warrants of small, fast-growing companies focused in technology, life sciences, health care information and services, business services, and other high-growth industries. These investments are considered Level 3 assets under ASC Topic 820 because there is no known or accessible market or market indices for these types of debt and equity instruments and, thus, RGC’s senior investment team must estimate the fair value of these investment securities based on models utilizing unobservable inputs.
The Audit Committee of the Company’s Board of Directors assists the Board of Directors in valuing investments that are not publicly traded or for which current market values are not readily available. Investments for which market quotations are readily available are valued using market quotations, which are generally obtained from independent pricing services, broker-dealers or market makers. With respect to portfolio investments for which market quotations are not readily available, the Company’s Board of Directors, with the assistance of the Audit Committee, RGC and its senior investment team and independent valuation agents, is responsible for determining, in good faith, the fair value in accordance with the valuation policy approved by the Board of Directors. If more than one valuation method is used to measure fair value, the results are evaluated and weighted, as appropriate, considering the reasonableness of the range indicated by those results. The Company considers a range of fair values based upon the valuation techniques utilized and selects the value within that range that was most representative of fair value based on current market conditions as well as other factors RGC’s senior investment team considers relevant.
The Company’s Board of Directors makes this fair value determination on a quarterly basis and any other time when a decision regarding the fair value of the portfolio investments is required. A determination of fair value involves subjective judgments and estimates and depends on the facts and circumstances. Due to the inherent uncertainty of determining the fair value of portfolio investments that do not have a readily available market value, the fair value of the investments may differ significantly from the values that would have been used had a readily available market value existed for such investments, and the differences could be material.
Valuation methodologies involve a significant degree of judgment. There is no single standard for determining the fair value of investments that do not have an active public market. Valuations of privately held investments are inherently uncertain, as they are based on estimates, and their values may fluctuate over time. The determination of fair value may differ materially from the values that would have been used if an active market for these investments existed. In some cases, the fair value of such investments is best expressed as a range of values derived utilizing different methodologies from which a fair value may then be determined.
Debt Investments
To determine the fair value of the Company’s debt investments, the Company compares the cost basis of the debt investment, which includes OID, to the resulting fair value determined using a discounted cash flow model, unless another model is more appropriate based on the circumstances at the measurement date. The discounted cash flow approach entails analyzing the interest rate spreads for recently completed financing transactions that are similar in nature to the Company’s investments, in order to determine a comparable range of effective market interest rates for its investments. The range of interest rate spreads utilized is based on borrowers with similar credit profiles. All remaining expected cash flows of the investment are discounted using this range of interest rates to determine a range of fair values for the debt investment.
This valuation process includes, among other things, evaluating the underlying investment performance, the portfolio company’s current financial condition and ability to raise additional capital, as well as macro-economic events that may impact valuations. These events include, but are not limited to, current market yields and interest rate spreads of similar securities as of the measurement date. Significant increases (decreases) in these unobservable inputs could result in a significantly higher (lower) fair value measurements.
Under certain circumstances, the Company may use an alternative technique to value the debt investments to be acquired by the Company that better reflects the fair value of the investment, such as the price paid or realized in a recently completed transaction or a binding offer received in an arms-length transaction, the use of multiple probability-weighted cash flow models when the expected future cash flows contain elements of variability or estimates of proceeds that would be received in a liquidation scenario.
24
Warrants
Fair value of warrants is primarily determined using a Black Scholes option-pricing model. Privately held warrants and equity-related securities are valued based on an analysis of various factors including, but not limited to, the following:
Under certain circumstances, the Company may use an alternative technique to value warrants that better reflects the warrants’ fair values, such as an expected settlement of a warrant in the near term, a model that incorporates a put feature associated with the warrant, or the price paid or realized in a recently completed transaction or binding offer received in an arms-length transaction. The fair value may be determined based on the expected proceeds to be received from such settlement or based on the net present value of the expected proceeds from the put option.
Equity Investments
The fair value of an equity investment in a privately held company is initially the face value of the amount invested. The Company adjusts the fair value of equity investments in private companies upon the completion of a new third-party round of equity financing subsequent to the Company’s investment. The Company may make adjustments to fair value, absent a new equity financing event, based upon positive or negative changes in a portfolio company’s financial or operational performance. The Company may also reference comparable transactions and/or secondary market transactions in connection with its determination of fair value. The fair value of an equity investment in a publicly traded company is based upon the closing public share price on the date of measurement. These assets are recorded at fair value on a recurring basis.
25
Investment Classification
The Company classifies its investments by level of affiliation and control. As defined in the 1940 Act, investee companies are deemed as affiliated investments when a company or individual possesses, or has the right to acquire within 60 days or less, beneficial ownership of
Investments are recognized when the Company assumes an obligation to acquire a financial instrument and assumes the risks for gains or losses related to that instrument. Investments are derecognized when the Company assumes an obligation to sell a financial instrument and foregoes the risks for gains or losses related to that instrument. Specifically, the Company records all security transactions on a trade date basis. Investments in other, non-security financial instruments, such as limited partnerships or private companies, are recorded on the basis of subscription date or redemption date, as applicable. Amounts for investments recognized or derecognized but not yet settled will be reported as receivables for investments sold and payables for investments acquired, respectively, on the Statements of Assets and Liabilities.
Income Taxes
The Company elected to be treated as a RIC under Subchapter M of the Code beginning with its taxable year ended December 31, 2016, currently qualifies as a RIC, and intends to qualify annually for the tax treatment applicable to RICs. A RIC generally is not subject to U.S. federal income taxes on distributed income and gains so long as it meets certain source-of-income and asset diversification requirements and it distributes at least 90% of its net ordinary income and net short-term capital gains in excess of its net long-term capital losses, if any, to its stockholders. So long as the Company maintains its status as a RIC, it generally will not be subject to U.S. federal income tax on any ordinary income or capital gains that it distributes at least annually to its stockholders as dividends. Rather, any tax liability related to income earned by the Company represents obligations of the Company’s investors and will not be reflected in the financial statements of the Company. The Company intends to make sufficient distributions to maintain its RIC status each year and it does not anticipate paying any material U.S. federal income taxes in the future.
Depending on the level of taxable income earned in a tax year, the Company may choose to carry forward such taxable income in excess of current year dividend distributions from such current year taxable income into the next tax year and pay a
Per Share Information
Basic and diluted earnings (loss) per common share is calculated using the weighted-average number of common shares outstanding for the period presented. For the three and nine months ended September 30, 2023 and 2022, basic and diluted earnings per share of common stock were the same because there were
26
Distributions
Distributions to common stockholders are recorded on the applicable record date. The amount, if any, to be distributed to common stockholders is determined by the Board of Directors each quarter and is generally based upon the Company's earnings estimated by management. Net realized capital gains, if any, are generally distributed at least annually. For more information, refer to "Note 9 – Net Assets."
Organization and Offering Costs
Organization costs include, among other things, the cost of organizing as a Maryland corporation, including the cost of legal services and other fees pertaining to the Company's organization, all of which are expensed as incurred. Offering costs include, among other things, legal fees and other costs pertaining to the preparation of the Company’s public and private offering materials as well as travel-related expenses related to the Company’s public and private offerings. Pursuant to the Advisory Agreement (as defined in Note 3 – Related Party Agreements and Transactions), the Company and RGC agreed that organization and offering costs incurred in connection with the Initial Private Offering (as defined in Note 9 – Net Assets) would be borne by the Company up to a maximum amount of $
Offering costs related to the Second Private Offering (as defined in Note 9 – Net Assets) were accumulated and charged to additional paid in capital at the time of closing beginning in 2019. These offering costs related to the Second Private Offering were subject to a cap of $
Offering costs related to the IPO were accumulated and charged to additional paid in capital at the time of closing in October 2021. The Company had accumulated and recorded $
Recent Accounting Pronouncements
In June 2022, the FASB issued ASU 2022-03, "Fair Value Measurement (Topic 820) - Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions", which was issued to (1) clarify the guidance in Topic 820, Fair Value Measurement, when measuring the fair value of an equity security subject to contractual restrictions that prohibit the sale of an equity security, (2) to amend a related illustrative example, and (3) to introduce new disclosure requirements for equity securities subject to contractual sale restrictions that are measured at fair value in accordance with Topic 820. The new guidance is effective for interim and annual periods beginning after December 15, 2023. The Company does not anticipate the new standard will have a material impact to the financial statements and related disclosures.
In July 2023, the SEC released final rules requiring disclosure by public companies of material cybersecurity incidents and policies and procedures related to cybersecurity risk management, strategy and governance ("Cybersecurity Rules"). The Cybersecurity Rules require public companies to (1) disclose cybersecurity incidents that detail the nature, scope, timing, and impact of such incidents and (2) disclose registrant's risk management, strategy, and governance regarding cybersecurity risks, including the board of directors’ oversight of cybersecurity risks and the impact of any such risks on its business strategy, results of operations and financial condition. The Cybersecurity Rules are incorporated under Regulation S-K as new Item 106. The Company intends to comply with the new disclosure requirements under the Cybersecurity Rules in its annual report on Form 10-K effective for the fiscal year ending December 15, 2023 or later.
27
Note 3 – Related Party Agreements and Transactions
Second Amended and Restated Advisory Agreement
On November 29, 2016, the Company’s Board of Directors approved an investment advisory agreement between RGC and the Company, under which RGC, subject to the overall supervision of the Board of Directors, manages the day-to-day operations of and provides investment advisory services to the Company (together with a subsequent amendment thereto, the “Prior Advisory Agreement”). On August 3, 2017, the Board of Directors approved certain amendments to the Prior Advisory Agreement (the “First Amended and Restated Advisory Agreement”) and recommended that the Company’s stockholders approve the First Amended and Restated Advisory Agreement. The First Amended and Restated Advisory Agreement became effective on September 12, 2017 upon approval by the stockholders at a special meeting of stockholders of the Company. On April 7, 2021, the Board of Directors approved certain additional amendments to the advisory agreement (the “Advisory Agreement”) at a virtual meeting and recommended that the Company’s stockholders approve the Advisory Agreement. In reliance upon certain exemptive relief granted by the SEC in connection with the global COVID-19 pandemic, the Board of Directors undertook to ratify the Advisory Agreement at its next in-person meeting which was held in July 2021. The Advisory Agreement became effective on May 27, 2021 upon approval by the stockholders at a special meeting of stockholders of the Company. The Advisory Agreement amended the Prior Advisory Agreement to include certain revisions to the management and incentive fee calculation mechanisms and clarify language relating to liquidity events. On May 2, 2023, the Company's Board of Directors renewed the Advisory agreement for a period of twelve months commencing May 27, 2023. Under the terms of the Advisory Agreement, RGC:
Pursuant to the Advisory Agreement, the Company pays RGC a fee for its investment advisory and management services consisting of
Base Management Fee
The base management fee is payable on the first day of each calendar quarter and is calculated on the Company's "Gross Assets" which, for purposes of the Advisory Agreement, is defined as the Company’s gross assets, including assets purchased with borrowed funds or other forms of leverage, as well as any PIK interest, as of the end of the most recently completed fiscal quarter. The base management fee will be an amount equal to
For the three and nine months ended September 30, 2023, RGC earned base management fees at a rate of
28
Incentive Fee
The incentive fee, which provides RGC with a share of the income that RGC generates for the Company, consists of an investment-income component and a capital-gains component, which are largely independent of each other, with the result that one component may be payable even if the other is not.
Under the investment-income component (the “Income Incentive Fee”), the Company pays RGC each quarter an incentive fee with respect to the Company’s pre-incentive fee net investment income. The Income Incentive Fee is calculated and payable quarterly in arrears based on the pre-incentive fee net investment income for the immediately preceding fiscal quarter. Payments based on pre-incentive fee net investment income will be based on the pre-incentive fee net investment income earned for the quarter. For this purpose, “pre-incentive fee net investment income” means interest income, dividend income and any other income (including any other fees, such as commitment, origination, structuring, diligence, managerial and consulting fees or other fees that the Company receives from portfolio companies) that the Company accrues during the fiscal quarter, minus the Company’s operating expenses for the quarter (including the base management fee, expenses payable under the amended and restated administration were deferred incentive fees payable, both of which are included in incentive fees payable on the Statements of Assets and Liabilities agreement with the Administrator (the “Administration Agreement”), and any dividends paid on any issued and outstanding preferred stock, but excluding the incentive fee). pre-incentive fee net investment income includes, in the case of investments with a deferred interest feature (such as OID accretion, debt instruments with pay in kind interest and zero coupon securities), accrued income the Company has not yet received in cash; provided, however, that the portion of the Income Incentive Fee attributable to deferred interest features will be paid, only if and to the extent received in cash, and any accrual thereof will be reversed if and to the extent such interest is reversed in connection with any write off or similar treatment of the investment giving rise to any deferred interest accrual, applied in each case in the order such interest was accrued. Such subsequent payments in respect of previously accrued income will not reduce the amounts payable for any quarter pursuant to the calculation of the Income Incentive Fee described above. Pre-incentive fee net investment income does not include any realized or unrealized capital gains (losses).
Pre-incentive fee net investment income, expressed as a rate of return on the value of the Company’s net assets (defined as total assets less liabilities) at the end of the immediately preceding fiscal quarter, will be compared to a “hurdle rate” of
Until the consummation of a Spin-Off transaction (defined below), in the event that (a) the sum of the Company’s cumulative net realized losses since the date of the Company’s election to be regulated as a BDC exceeded
29
Under the capital gains component of the incentive fee (the “Capital Gains Fee”), the Company will pay RGC, as of the end of each calendar year,
For the three and nine months ended September 30, 2023, RGC earned incentive fees of $
The capital gains incentive fee consists of fees related to realized gains and losses and unrealized capital losses. With respect to the incentive fee expense accrual related to the capital gains incentive fee, U.S. GAAP requires that the capital gains incentive fee accrual consider the cumulative aggregate unrealized gains in the calculation, as a capital gains incentive fee would be payable if such unrealized gains were realized even though such unrealized gains are not permitted to be considered in calculating the fee actually payable under the Advisory Agreement. As of each of September 30, 2023 and December 31, 2022, there was
Spin-Off Incentive Fee
The Income Incentive Fee will be payable in connection with a Public Fund Spin-Off as follows. The Income Incentive Fee will be calculated as of the date of the completion of each Public Fund Spin-Off and will equal the amount of Income Incentive Fee that would be payable to RGC if (1) all of the Company’s investments were liquidated for their current value and any unamortized deferred portfolio investment-related fees would be deemed accelerated, (2) the proceeds from such liquidation were used to pay all of the Company’s outstanding liabilities, and (3) the remainder were distributed to the Company’s stockholders and paid as incentive fee in accordance with the Income Incentive Fee described in clauses (1) and (2) above for determining the amount of the Income Incentive Fee; provided, however, that in no event will the Income Incentive Fee paid in connection with the completion of the Public Fund Spin-Off (x) include the portion of the Income Incentive Fee attributable to deferred interest features of a particular investment that is not transferred pursuant to the Public Fund Spin-Off until such time as the deferred interest is received in cash, or (y) exceed
The Capital Gains Fee will be payable in respect of the exchanged shares of the Company’s common stock in connection with the Public Fund Spin-Off and will be calculated as of the date of the completion of the Public Fund Spin-Off as if such date were a calendar year-end for purposes of calculating and paying the Capital Gains Fee.
No Income Incentive Fee or Capital Gains Fee will be payable in connection with the Public Fund Spin-Off unless, on the date of the completion of the Public Fund Spin-Off, the sum of the Company’s (i) pre-incentive fee net investment income and (ii) realized capital gains less realized capital losses and unrealized capital losses from the date of the Company’s election to be regulated as a BDC through, and including, the date of the completion of the Public Fund Spin-Off, is greater than
30
Administration Agreement
The Company reimburses the Administrator for the allocable portion of overhead expenses incurred by the Administrator in performing its obligations under the Administration Agreement, including furnishing the Company with office facilities, equipment and clerical, bookkeeping and recordkeeping services at such facilities, as well as providing other administrative services. In addition, the Company reimburses the Administrator for the fees and expenses associated with performing compliance functions, and the Company’s allocable portion of the compensation of certain of its officers, including the Company’s Chief Financial Officer, Chief Compliance Officer and any administrative support staff, as well as any expenses paid by the Administrator on the Company's behalf.
For the three months ended September 30, 2023, the Company incurred $
License Agreement
The Company has entered into a license agreement with RGC (the “License Agreement”) pursuant to which RGC has granted the Company a personal, non-exclusive, royalty-free right and license to use the name “Runway Growth Finance.” Under the License Agreement, the Company has the right to use the “Runway Growth Finance” name for so long as RGC or one of its affiliates remains the Company’s investment adviser. Other than with respect to this limited license, the Company has no legal right to the “Runway Growth Finance” name.
Strategic Relationship
In December 2016, the Company and RGC entered into a strategic relationship with Oaktree Capital Management, L.P (“Oaktree”). In connection with the strategic relationship, OCM Growth Holdings ("OCM Growth") purchased an aggregate of
(Delaware), L.P. (together with OCM Growth, the “OCM Holders”), each an affiliate of Oaktree, own
In connection with OCM Growth’s commitment, the Company entered into a stockholder agreement, dated December 15, 2016, with OCM Growth, pursuant to which OCM Growth has a right to nominate a member of the Company’s Board of Directors for election for so long as OCM Growth holds shares of the Company’s common stock in an amount equal to, in the aggregate, at least one-third (
31
Note 4 – Investments
Control and Affiliate Investments
The Company classifies its investment portfolio by level of affiliation and control in accordance with the requirements of the 1940 Act. As defined in the 1940 Act, investee companies are deemed as affiliated investments when a company or individual possesses, or has the right to acquire within 60 days or less, beneficial ownership of
The Company’s affiliate and control investments as of September 30, 2023 along with the transactions during the nine months ended September 30, 2023 are as follows:
|
|
|
|
|
|
For the Nine Months Ended September 30, 2023 |
|
||||||||||||||||||||||||||||||||
|
|
|
|
|
|
Amount of Investment Income Earned 2023 |
|
|
Fair Value as of December 31, 2022 |
|
|
Gross Additions(1) |
|
|
Gross Reductions(2) |
|
|
Net Realized Gain (Loss) |
|
|
Net Change in Unrealized Gain (Loss) |
|
|
Fair Value as of September 30, 2023(3) |
|
||||||||||||||
Portfolio Company |
|
Investment Description |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||
Affiliate Investments |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
|
Senior Secured Term Loans |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
|
Gynesonics, Inc. |
|
SOFR+ |
|
$ |
|
|
|
$ |
|
— |
|
|
$ |
|
|
|
$ |
|
— |
|
|
$ |
|
— |
|
|
$ |
|
( |
) |
|
$ |
|
|
||||
|
Total Senior Secured Term Loans |
|
|
|
|
|
|
|
— |
|
|
|
|
|
|
|
|
— |
|
|
|
|
— |
|
|
|
|
( |
) |
|
|
|
|
||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
|
Preferred Stocks |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
|
Gynesonics, Inc. |
|
Series A-2 Preferred Stock |
|
|
|
— |
|
|
|
|
— |
|
|
|
|
|
|
|
|
— |
|
|
|
|
— |
|
|
|
|
( |
) |
|
|
|
|
|||
|
Total Preferred Stocks |
|
|
|
— |
|
|
|
|
— |
|
|
|
|
|
|
|
|
— |
|
|
|
|
— |
|
|
|
|
( |
) |
|
|
|
|
|||||
|
Common Stocks |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
|
Coginiti Corp |
|
Common Stock |
|
|
|
— |
|
|
|
|
|
|
|
|
— |
|
|
|
|
— |
|
|
|
|
— |
|
|
|
|
( |
) |
|
|
|
|
|||
|
Total Common Stocks |
|
|
|
— |
|
|
|
|
|
|
|
|
— |
|
|
|
|
— |
|
|
|
|
— |
|
|
|
|
( |
) |
|
|
|
|
|||||
|
Warrants |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
|
Coginiti Corp |
|
Warrant for common stock, expires 3/09/2030 |
|
|
|
— |
|
|
|
|
|
|
|
|
— |
|
|
|
|
— |
|
|
|
|
— |
|
|
|
|
( |
) |
|
|
|
|
|||
|
Gynesonics, Inc. |
|
Success fee |
|
|
|
— |
|
|
|
|
— |
|
|
|
|
|
|
|
|
— |
|
|
|
|
— |
|
|
|
|
|
|
|
|
|
||||
|
Total Warrants |
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
|
— |
|
|
|
|
— |
|
|
|
|
( |
) |
|
|
|
|
||||||
Total Affiliate Investments |
|
$ |
|
|
|
$ |
|
|
|
$ |
|
|
|
$ |
|
— |
|
|
$ |
|
— |
|
|
$ |
|
( |
) |
|
$ |
|
|
||||||||
Control Investments |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
|
Senior Secured Term Loans |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
|
Pivot3, Inc. |
|
LIBOR+ |
|
|
|
— |
|
|
|
|
|
|
|
|
— |
|
|
|
|
( |
) |
|
|
|
— |
|
|
|
|
|
|
|
|
|
||||
|
Total Senior Secured Term Loans |
|
|
|
— |
|
|
|
|
|
|
|
|
— |
|
|
|
|
( |
) |
|
|
|
— |
|
|
|
|
|
|
|
|
|
||||||
Total Control Investments |
|
$ |
|
— |
|
|
$ |
|
|
|
$ |
|
— |
|
|
$ |
|
( |
) |
|
$ |
|
— |
|
|
$ |
|
|
|
$ |
|
|
32
The Company’s affiliate and control investments as of December 31, 2022, along with the transactions during the year ended December 31, 2022 are as follows:
|
|
|
|
|
|
|
|
|
|
For the Year Ended December 31, 2022 |
|
|
|
|
|
||||||||||||||||||||||||
|
|
|
|
|
|
Amount of Investment Income Earned 2022 |
|
|
Fair Value as of December 31, 2021 |
|
|
Gross Additions(1) |
|
|
Gross Reductions(2) |
|
|
Net Realized Gain (Loss) |
|
|
Net Change in Unrealized Gain (Loss) |
|
|
Fair Value as of December 31, 2022(3) |
|
||||||||||||||
Portfolio Company |
|
Investment Description |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||
Affiliate Investments |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
|
Senior Secured Term Loans |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
|
Coginiti Corp |
|
LIBOR+ |
|
$ |
|
|
|
$ |
|
— |
|
|
$ |
|
|
|
$ |
|
( |
) |
|
$ |
|
— |
|
|
$ |
|
— |
|
|
$ |
|
— |
|
|||
|
Total Senior Secured Term Loans |
|
|
|
|
|
|
|
— |
|
|
|
|
|
|
|
|
( |
) |
|
|
|
— |
|
|
|
|
— |
|
|
|
|
— |
|
|||||
|
Common Stocks |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
|
Coginiti Corp |
|
Common Stock |
|
|
|
— |
|
|
|
|
— |
|
|
|
|
|
|
|
|
— |
|
|
|
|
— |
|
|
|
|
( |
) |
|
|
|
|
|||
|
Total Common Stocks |
|
|
|
|
— |
|
|
|
|
— |
|
|
|
|
|
|
|
|
— |
|
|
|
|
— |
|
|
|
|
( |
) |
|
|
|
|
||||
|
Warrants |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
|
Coginiti Corp |
|
Warrant for Common Stock, exercise price $ |
|
|
|
— |
|
|
|
|
— |
|
|
|
|
|
|
|
|
— |
|
|
|
|
— |
|
|
|
|
( |
) |
|
|
|
|
|||
|
Total Warrants |
|
|
|
— |
|
|
|
|
— |
|
|
|
|
|
|
|
|
— |
|
|
|
|
— |
|
|
|
|
( |
) |
|
|
|
|
|||||
|
Total Affiliate Investments |
|
$ |
|
|
|
$ |
|
— |
|
|
$ |
|
|
|
$ |
|
( |
) |
|
$ |
|
— |
|
|
$ |
|
( |
) |
|
$ |
|
|
||||||
Control Investments |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
|
Senior Secured Term Loans |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
|
Mojix, Inc. |
|
LIBOR+ |
|
$ |
|
|
|
$ |
|
|
|
$ |
|
|
|
$ |
|
( |
) |
|
$ |
|
— |
|
|
$ |
|
( |
) |
|
$ |
|
— |
|
||||
|
|
|
|
LIBOR+ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
( |
) |
|
|
|
— |
|
|
|
|
( |
) |
|
|
|
— |
|
|||
|
|
|
|
LIBOR+ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
( |
) |
|
|
|
— |
|
|
|
|
( |
) |
|
|
|
— |
|
|||
|
|
|
|
LIBOR+ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
( |
) |
|
|
|
— |
|
|
|
|
( |
) |
|
|
|
— |
|
|||
|
|
|
|
LIBOR+ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
( |
) |
|
|
|
— |
|
|
|
|
( |
) |
|
|
|
— |
|
|||
|
|
|
|
LIBOR+ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
( |
) |
|
|
|
— |
|
|
|
|
( |
) |
|
|
|
— |
|
|||
|
Pivot3, Inc. |
|
LIBOR+ |
|
|
|
— |
|
|
|
|
|
|
|
|
— |
|
|
|
|
— |
|
|
|
|
— |
|
|
|
|
( |
) |
|
|
|
|
|||
|
Total Senior Secured Term Loans |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
( |
) |
|
|
|
— |
|
|
|
|
( |
) |
|
|
|
|
|||||||
|
Preferred Stocks |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||
|
Mojix, Inc. |
|
Series A-1 Preferred Stock |
|
|
|
|
|
|
|
|
|
|
|
— |
|
|
|
|
( |
) |
|
|
|
— |
|
|
|
|
( |
) |
|
|
|
— |
|
|||
|
Pivot3 Holdings, Inc. |
|
Series 1 Preferred Stock |
|
|
|
— |
|
|
|
|
— |
|
|
|
|
— |
|
|
|
|
— |
|
|
|
|
( |
) |
|
|
|
|
|
|
|
— |
|
||
|
Total Preferred Stocks |
|
|
|
|
|
|
|
|
|
|
|
— |
|
|
|
|
( |
) |
|
|
|
( |
) |
|
|
|
|
|
|
|
— |
|
||||||
|
Warrants |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||
|
Mojix, Inc. |
|
Warrant for Common Stock, exercise price $ |
|
|
|
— |
|
|
|
|
— |
|
|
|
|
— |
|
|
|
|
( |
) |
|
|
|
— |
|
|
|
|
|
|
|
|
— |
|
||
|
|
|
|
Warrant for Common Stock, exercise price $ |
|
|
|
— |
|
|
|
|
— |
|
|
|
|
— |
|
|
|
|
( |
) |
|
|
|
— |
|
|
|
|
|
|
|
|
— |
|
|
|
|
|
|
Warrant for Common Stock, exercise price $ |
|
|
|
— |
|
|
|
|
— |
|
|
|
|
— |
|
|
|
|
( |
) |
|
|
|
— |
|
|
|
|
|
|
|
|
— |
|
|
|
Total Warrants |
|
|
|
— |
|
|
|
|
— |
|
|
|
|
— |
|
|
|
|
( |
) |
|
|
|
— |
|
|
|
|
|
|
|
|
— |
|
||||
Total Control Investments |
|
$ |
|
|
|
$ |
|
|
|
$ |
|
|
|
$ |
|
( |
) |
|
$ |
|
( |
) |
|
$ |
|
( |
) |
|
$ |
|
|
33
Portfolio Composition
The following tables show the fair value of the Company's portfolio of investments by geographic region and industry as of September 30, 2023 and December 31, 2022:
|
|
September 30, 2023 |
|
December 31, 2022 |
||||||||||||||||
Geographic Region |
|
Investments at Fair Value |
|
|
Percentage of Net Assets |
|
Investments at Fair Value |
|
|
Percentage of Net Assets |
||||||||||
Western United States |
|
$ |
|
|
|
|
|
% |
|
$ |
|
|
|
|
|
% |
||||
Northeastern United States |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Midwestern United States |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
South Central United States |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
United Kingdom |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Germany |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Southeastern United States |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Northwestern United States |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Canada |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Total |
|
$ |
|
|
|
|
|
% |
|
$ |
|
|
|
|
|
% |
|
|
September 30, 2023 |
|
December 31, 2022 |
||||||||||||||||
Industry |
|
Investments at Fair Value |
|
|
Percentage of Net Assets |
|
Investments at Fair Value |
|
|
Percentage of Net Assets |
||||||||||
Health Care Technology |
|
$ |
|
|
|
|
|
% |
|
|
|
|
|
|
|
% |
||||
Application Software |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Data Processing & Outsourced Services |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Human Resource & Employment Services |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Internet Software and Services |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
System Software |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Property & Casualty Insurance |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Internet & Direct Marketing Retail |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Electronic Equipment & Instruments |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Education Services |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Health Care Equipment |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Technology Hardware, Storage & Peripherals |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Specialized Consumer Services |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Biotechnology |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Computer & Electronics Retail |
|
|
|
- |
|
|
|
- |
|
|
|
|
|
|
|
|
|
|
||
Total |
|
$ |
|
|
|
|
|
% |
|
$ |
|
|
|
|
|
% |
Derivative Financial Instruments
In the normal course of business, the Company may utilize derivative contracts in connection with its investment activities. Investments in derivative contracts are subject to additional risks that can result in a loss of all or part of an investment. The derivative activities and exposure to derivative contracts primarily involve equity price risks. In addition to the primary underlying risk, additional counterparty risk exists due to the potential inability of counterparties to meet the terms of their contracts.
Warrants provide exposure and potential gains upon equity gains of the portfolio company’s equity value. A warrant has a limited life and expires on a certain date. As a warrant’s expiration date approaches, the time value of the warrant will decline. In addition, if the stock underlying the warrant declines in price, the intrinsic value of an “in the money” warrant will decline. Further, if the price of the stock underlying the warrant does not exceed the strike price of the warrant on the expiration date, the warrant will expire worthless. As a result, there is the potential for the entire value of an investment in a warrant to be lost. The Company’s volume of warrant investment activity is closely correlated to its primary senior secured loans to portfolio companies. For the three and nine months ended September 30, 2023, the Company had net realized gains (losses) of $
Counterparty risk exists from the potential failure of an issuer of warrants to settle its exercised warrants. The maximum risk of loss from counterparty risk is the fair value of the contracts and the purchase price of the warrants. The Company’s Board of Directors considers the effects of counterparty risk when determining the fair value of its investments in warrants.
34
Note 5 – Fair Value of Financial Instruments
The Company’s assets recorded at fair value have been categorized based upon a fair value hierarchy in accordance with ASC Topic 820. Refer to "Note 2 – Summary of Significant Accounting Policies" for a discussion of the Company’s policies.
Investments measured at fair value on a recurring basis are categorized in the tables below based upon the lowest level of significant input to the valuations as of September 30, 2023 and December 31, 2022 (in thousands):
|
|
As of September 30, 2023 |
|
|||||||||||||||||
|
|
Level 1 |
|
|
Level 2 |
|
|
Level 3 |
|
|
Total |
|
||||||||
Portfolio Investments |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Senior Secured Term Loans |
|
$ |
|
|
|
$ |
|
|
|
$ |
|
|
|
$ |
|
|
||||
Second Lien Term Loans |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Preferred Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Warrants |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Total Portfolio Investments |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Cash equivalents |
|
|
|
|
|
|
|
— |
|
|
|
|
— |
|
|
|
|
|
||
Total |
|
$ |
|
|
|
$ |
|
|
|
$ |
|
|
|
$ |
|
|
|
|
As of December 31, 2022 |
|
|||||||||||||||||
|
|
Level 1 |
|
|
Level 2 |
|
|
Level 3 |
|
|
Total |
|
||||||||
Portfolio Investments |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Senior Secured Term Loans |
|
$ |
|
|
|
$ |
|
|
|
$ |
|
|
|
$ |
|
|
||||
Second Lien Term Loans |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Preferred Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Warrants |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Total Portfolio Investments |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Cash equivalents |
|
|
|
|
|
|
|
— |
|
|
|
|
— |
|
|
|
|
|
||
Total |
|
$ |
|
|
|
$ |
|
|
|
$ |
|
|
|
$ |
|
|
The Company transfers investments in and out of Levels 1, 2 and 3 as of the beginning balance sheet date, based on changes in the use of observable and unobservable inputs utilized to perform the valuation for the period.
35
The following table presents a rollforward of Level 3 assets measured at fair value as of September 30, 2023 (in thousands):
|
|
Preferred Stock |
|
|
Common Stock |
|
|
Senior Secured Term Loans |
|
|
Second Lien Term Loans |
|
|
Warrants |
|
|
Total |
|
||||||||||||
Fair value at December 31, 2022 |
|
$ |
|
|
|
$ |
|
|
|
$ |
|
|
|
$ |
|
|
|
$ |
|
|
|
$ |
|
|
||||||
Transfers out of Level 3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
( |
) |
|
|
|
( |
) |
||||
Purchases of investments(1) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
PIK interest |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Sales or repayments of investments(1) |
|
|
|
|
|
|
|
|
|
|
|
( |
) |
|
|
|
|
|
|
|
|
|
|
|
( |
) |
||||
Net realized gain (loss) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
( |
) |
|
|
|
( |
) |
||||
Net change in unrealized gain (loss) |
|
|
|
( |
) |
|
|
|
( |
) |
|
|
|
( |
) |
|
|
|
|
|
|
|
( |
) |
|
|
|
( |
) |
|
Amortization of fixed income premiums or accretion of discounts |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Fair value at September 30, 2023 |
|
$ |
|
|
|
$ |
|
|
|
$ |
|
|
|
$ |
|
|
|
$ |
|
|
|
$ |
|
|
||||||
Net change in unrealized gain (loss) on Level 3 investments still held as of September 30, 2023 |
|
$ |
|
( |
) |
|
$ |
|
( |
) |
|
$ |
|
( |
) |
|
$ |
|
|
|
$ |
|
( |
) |
|
$ |
|
( |
) |
The following table presents a rollforward of Level 3 assets measured at fair value as of September 30, 2022 (in thousands):
|
|
Preferred Stock |
|
|
Common Stock |
|
|
Senior Secured Term Loans |
|
|
Second Lien Term Loans |
|
|
Warrants |
|
|
Total |
|
||||||||||||
Fair value at December 31, 2021 |
|
$ |
|
|
|
$ |
|
|
|
$ |
|
|
|
$ |
|
|
|
$ |
|
|
|
$ |
|
|
||||||
Transfers out of Level 3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
( |
) |
|
|
|
( |
) |
||||
Purchases of investments(1) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
PIK interest |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Sales or repayments of investments(1) |
|
|
|
( |
) |
|
|
|
|
|
|
|
( |
) |
|
|
|
|
|
|
|
( |
) |
|
|
|
( |
) |
||
Net realized gain (loss) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
( |
) |
|
|
|
( |
) |
||||
Net change in unrealized gain (loss) |
|
|
|
( |
) |
|
|
|
( |
) |
|
|
|
( |
) |
|
|
|
( |
) |
|
|
|
|
|
|
|
( |
) |
|
Amortization of fixed income premiums or accretion of discounts |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Fair Value at September 30, 2022 |
|
$ |
|
|
|
$ |
|
|
|
$ |
|
|
|
$ |
|
|
|
$ |
|
|
|
$ |
|
|
||||||
Net change in unrealized gain (loss) on Level 3 investments still held as of September 30, 2022 |
|
$ |
|
( |
) |
|
$ |
|
( |
) |
|
$ |
|
( |
) |
|
$ |
|
( |
) |
|
$ |
|
( |
) |
|
$ |
|
( |
) |
36
The following table provides quantitative information regarding Level 3 fair value measurements as of September 30, 2023 (in thousands):
Description |
|
Fair Value |
|
|
Valuation Technique |
|
Unobservable Inputs |
|
Range (Weighted Average) |
||
Senior Secured Term Loans(1) |
|
$ |
|
|
|
Discounted Cash Flow analysis |
|
Discount rate |
|
||
|
|
|
|
|
|
Market approach |
|
Origination yield |
|
||
|
|
|
|
|
|
PWERM |
|
Discount rate |
|
||
Second Lien Term Loans(1) |
|
|
|
|
|
Discounted Cash Flow analysis |
|
Discount rate |
|
||
|
|
|
|
|
|
Market approach |
|
Origination yield |
|
||
Preferred Stock |
|
|
|
|
|
Recent private market and merger and acquisition transaction prices |
|
N/A |
|
N/A |
|
|
|
|
|
|
|
Option pricing model |
|
Risk-Free Rate |
|
||
|
|
|
|
|
|
|
|
Average industry volatility |
|
||
|
|
|
|
|
|
|
|
Estimated time to exit |
|
||
|
|
|
|
|
|
|
|
Revenue multiples |
|
||
Common Stock |
|
|
|
|
|
Recent private market and merger and acquisition transaction prices |
|
N/A |
|
N/A |
|
Warrants(2) |
|
|
|
|
|
Option pricing model |
|
Risk-free interest rate |
|
||
|
|
|
|
|
|
|
|
Average industry volatility |
|
||
|
|
|
|
|
|
|
|
Estimated time to exit |
|
||
|
|
|
|
|
|
|
|
Revenue multiples |
|
||
|
|
|
|
|
|
PWERM |
|
Discount rate |
|
||
|
|
|
|
|
|
|
|
Revenue multiples |
|
||
Total Level 3 Investments |
|
$ |
|
|
|
|
|
|
|
|
The following table provides quantitative information regarding Level 3 fair value measurements as of December 31, 2022 (in thousands):
Description |
|
Fair Value |
|
|
Valuation Technique |
|
Unobservable Inputs |
|
Range (Weighted Average) |
||
Senior Secured Term Loans(1) |
|
$ |
|
|
|
Discounted Cash Flow analysis |
|
Discount rate |
|
||
|
|
|
|
|
|
Market approach |
|
Origination yield |
|
||
|
|
|
|
|
|
PWERM |
|
Discount rate |
|
||
Second Lien Term Loans(1) |
|
|
|
|
|
Discounted Cash Flow analysis |
|
Discount rate |
|
||
|
|
|
|
|
|
Market approach |
|
Origination yield |
|
||
Preferred Stock |
|
|
|
|
|
Recent private market and merger and acquisition transaction prices |
|
N/A |
|
N/A |
|
Common Stock |
|
|
|
|
|
Recent private market and merger and acquisition transaction prices |
|
N/A |
|
N/A |
|
Warrants(2) |
|
|
|
|
|
Option pricing model |
|
Risk-free interest rate |
|
||
|
|
|
|
|
|
|
|
Average industry volatility |
|
||
|
|
|
|
|
|
|
|
Estimated time to exit |
|
||
|
|
|
|
|
|
|
|
Revenue multiples |
|
||
|
|
|
|
|
|
PWERM |
|
Discount rate |
|
||
|
|
|
|
|
|
|
|
Revenue multiples |
|
||
Total Level 3 Investments |
|
$ |
|
|
|
|
|
|
|
|
37
Fair Value of Financial Instruments Reported at Cost
The fair value of the Company’s Credit Facility, April 2026 Notes, December 2026 Notes, July 2027 Notes, August 2027 Notes, and December 2027 Notes (as defined in "Note 7 – Borrowings") is estimated using the relative market yield approach. The fair value of the Company's Credit Facility, December 2026 Notes and August 2027 Notes are estimated using Level 3 inputs by discounting remaining payments using comparable market rates or market quotes for similar instruments at the measurement date. The fair value of the Company's July 2027 Notes and December 2027 Notes is based on vendor pricing received by the Company, which is considered a Level 2 input, and reflects the market close price of the notes traded on the Nasdaq Global Select Market LLC under the symbol "RWAYL" and "RWAYZ", respectively.
As of both September 30, 2023, and December 31, 2022, the carrying values of the Credit Facility, April 2026 Notes, July 2027 Notes, August 2027 Notes, and December 2027 Notes approximate fair value. As of September 30, 2023, the fair value of the December 2026 Notes was approximately $
Note 6 –
In the normal course of business, the Company maintains its cash balances at large, high credit-quality financial institutions, which at times may exceed federally insured limits. The Company is subject to credit risk to the extent that any financial institution with which it conducts business is unable to fulfill contractual obligations on its behalf. The Company monitors the financial condition of those financial institutions and believes that risk of loss associated with any uninsured balance is remote.
In the event that a portfolio company completely fails to perform according to the terms of their loan agreement, the amount of loss due to credit risk from the Company's investments would equal the sum of the Company’s recorded investments in the portfolio company and the portion of unfunded commitments currently eligible to be drawn. Refer to "Note 8 – Commitments and Contingencies" for a summary of the aggregate balance of unfunded commitments as of September 30, 2023. The Company collateralizes its investments by obtaining a first priority security interest in a portfolio company’s assets, which may include its intellectual property.
As of September 30, 2023 and December 31, 2022, the Company’s
38
Note 7 – Borrowings
The following table shows the Company's borrowings as of September 30, 2023 and December 31, 2022 (in thousands):
|
|
September 30, 2023 |
|
|
December 31, 2022 |
|
||||||||||||||||||||||||||||||||||
|
|
Total Commitment |
|
|
Principal |
|
|
Deferred Debt Cost(1) |
|
|
Carrying Value |
|
|
Total Commitment |
|
|
Principal |
|
|
Deferred Debt Cost(1) |
|
|
Carrying Value |
|
||||||||||||||||
Credit Facility |
|
$ |
|
|
|
$ |
|
|
|
$ |
|
( |
) |
|
$ |
|
|
|
$ |
|
|
|
$ |
|
|
|
$ |
|
( |
) |
|
$ |
|
|
||||||
April 2026 Notes |
|
|
|
|
|
|
|
|
|
|
|
( |
) |
|
|
|
|
|
|
|
— |
|
|
|
|
— |
|
|
|
|
— |
|
|
|
|
— |
|
|||
December 2026 Notes |
|
|
|
|
|
|
|
|
|
|
|
( |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
( |
) |
|
|
|
|
||||||
July 2027 Notes |
|
|
|
|
|
|
|
|
|
|
|
( |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
( |
) |
|
|
|
|
||||||
August 2027 Notes |
|
|
|
|
|
|
|
|
|
|
|
( |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
( |
) |
|
|
|
|
||||||
December 2027 Notes |
|
|
|
|
|
|
|
|
|
|
|
( |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
( |
) |
|
|
|
|
||||||
Total |
|
$ |
|
|
|
$ |
|
|
|
$ |
|
( |
) |
|
$ |
|
|
|
$ |
|
|
|
$ |
|
|
|
$ |
|
( |
) |
|
$ |
|
|
(1) Net of accumulated amortization.
For the three months ended September 30, 2023 and 2022, the components of interest expense, amortization of deferred debt costs, unused fees on the Credit Facility (as defined below), and any other costs associated with the Company's borrowings were as follows (dollars in thousands):
|
|
Interest Expense |
|
|
Amortization of |
|
|
Unused Facility and |
|
|
Total Interest and Other Debt Financing Expenses |
|
|
Weighted Average |
|||||||||||
Three Months Ended September 30, 2023 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
Credit Facility |
|
$ |
|
|
|
$ |
|
|
|
$ |
|
|
|
$ |
|
|
|
|
|
% |
|||||
April 2026 Notes |
|
|
|
|
|
|
|
|
|
|
|
— |
|
|
|
|
|
|
|
|
|
||||
December 2026 Notes |
|
|
|
|
|
|
|
|
|
|
|
— |
|
|
|
|
|
|
|
|
|
||||
July 2027 Notes |
|
|
|
|
|
|
|
|
|
|
|
— |
|
|
|
|
|
|
|
|
|
||||
August 2027 Notes |
|
|
|
|
|
|
|
|
|
|
|
— |
|
|
|
|
|
|
|
|
|
||||
December 2027 Notes |
|
|
|
|
|
|
|
|
|
|
|
— |
|
|
|
|
|
|
|
|
|
||||
Total |
|
$ |
|
|
|
$ |
|
|
|
$ |
|
|
|
$ |
|
|
|
|
|
% |
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
Three Months Ended September 30, 2022 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
Credit Facility |
|
$ |
|
|
|
$ |
|
|
|
$ |
|
|
|
$ |
|
|
|
|
|
% |
|||||
December 2026 Notes |
|
|
|
|
|
|
|
|
|
|
|
— |
|
|
|
|
|
|
|
|
|
||||
July 2027 Notes |
|
|
|
|
|
|
|
|
|
|
|
— |
|
|
|
|
|
|
|
|
|
||||
August 2027 Notes |
|
|
|
|
|
|
|
|
|
|
|
— |
|
|
|
|
|
|
|
|
|
||||
Total |
|
$ |
|
|
|
$ |
|
|
|
$ |
|
|
|
$ |
|
|
|
|
|
% |
For the nine months ended September 30, 2023 and 2022, the components of interest expense, amortization of deferred debt costs, unused fees on the Credit Facility (as defined below), and any other costs associated with the Company's borrowings were as follows (dollars in thousands):
|
|
Interest Expense |
|
|
Amortization of |
|
|
Unused Facility and |
|
|
Total Interest and Other Debt Financing Expenses |
|
|
Weighted Average |
|||||||||||
Nine Months Ended September 30, 2023 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
Credit Facility |
|
$ |
|
|
|
$ |
|
|
|
$ |
|
|
|
$ |
|
|
|
|
|
% |
|||||
April 2026 Notes |
|
|
|
|
|
|
|
|
|
|
|
— |
|
|
|
|
|
|
|
|
|
||||
December 2026 Notes |
|
|
|
|
|
|
|
|
|
|
|
— |
|
|
|
|
|
|
|
|
|
||||
July 2027 Notes |
|
|
|
|
|
|
|
|
|
|
|
— |
|
|
|
|
|
|
|
|
|
||||
August 2027 Notes |
|
|
|
|
|
|
|
|
|
|
|
— |
|
|
|
|
|
|
|
|
|
||||
December 2027 Notes |
|
|
|
|
|
|
|
|
|
|
|
— |
|
|
|
|
|
|
|
|
|
||||
Total |
|
$ |
|
|
|
$ |
|
|
|
$ |
|
|
|
$ |
|
|
|
|
|
% |
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
Nine Months Ended September 30, 2022 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
Credit Facility |
|
$ |
|
|
|
$ |
|
|
|
$ |
|
|
|
$ |
|
|
|
|
|
% |
|||||
December 2026 Notes |
|
|
|
|
|
|
|
|
|
|
|
— |
|
|
|
|
|
|
|
|
|
||||
July 2027 Notes |
|
|
|
|
|
|
|
|
|
|
|
— |
|
|
|
|
|
|
|
|
|
||||
August 2027 Notes |
|
|
|
|
|
|
|
|
|
|
|
— |
|
|
|
|
|
|
|
|
|
||||
Total |
|
$ |
|
|
|
$ |
|
|
|
$ |
|
|
|
$ |
|
|
|
|
|
% |
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
39
Credit Facility
On May 31, 2019, the Company entered into a Credit Agreement with KeyBank National Association, acting as administrative agent and syndication agent and the other lenders party thereto, which initially provided the Company with a $
Borrowings under the Credit Facility bear interest on a per annum rate equal to the Adjusted Term Secured Overnight Financing Rate (“SOFR”) plus an applicable margin rate that ranges from
The Credit Facility is collateralized by all eligible investment assets held by the Company. The Credit Facility contains representations, warranties, and affirmative and negative covenants customary for secured financings of this type, including certain financial covenants such as a consolidated tangible net worth requirement and a required asset coverage ratio.
For the three and nine months ended September 30, 2023, the weighted average outstanding principal balance was $
2026 Notes
On December 10, 2021, the Company entered into a master note purchase agreement, completing a private debt offering of $
December 2026 Notes
The December 2026 Notes bear an interest rate of
Aggregate costs in connection with the December 2026 Notes issuance were $
April 2026 Notes
The April 2026 Notes bear an interest rate of
Aggregate costs in connection with the April 2026 Notes issuance were $
40
2027 Notes
July 2027 Notes
On July 28, 2022, the Company issued and sold $
The July 2027 Notes bear an interest rate of
Aggregate costs in connection with the July 2027 Notes issuance, including the underwriter’s discount and commissions, were $
August 2027 Notes
On August 31, 2022, the Company issued and sold a private debt offering of $
The August 2027 Notes bear an interest rate of
Aggregate costs in connection with the August 2027 Notes issuance were $
December 2027 Notes
On December 7, 2022, the Company issued and sold $
The December 2027 Notes bear an interest rate of
Aggregate costs in connection with the December 2027 Notes issuance, including the underwriter's discount and commissions, were $
41
Note 8 – Commitments and Contingencies
Commitments
The following table provides the Company’s contractual obligations as of September 30, 2023 (in thousands):
|
|
|
|
|
|
Payments Due by Period |
|
||||||||||||||||||
Contractual Obligations (1) |
Total |
|
|
Less than 1 Year |
|
|
|
1-3 years |
|
|
|
3-5 years |
|
|
More than 5 Years |
|
|||||||||
Borrowings (2) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
Credit Facility |
|
$ |
|
|
|
$ |
|
— |
|
|
$ |
|
|
|
$ |
|
— |
|
|
$ |
|
— |
|
||
2026 Notes |
|
|
|
|
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
|
— |
|
|||
2027 Notes |
|
|
|
|
|
|
|
— |
|
|
|
|
— |
|
|
|
|
|
|
|
|
— |
|
||
Total Borrowings |
|
|
|
|
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
|
— |
|
|||
Deferred Incentive Fees |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
Total |
|
$ |
|
|
|
$ |
|
|
|
$ |
|
|
|
$ |
|
|
|
$ |
|
|
The following table provides the Company’s contractual obligations as of December 31, 2022 (in thousands):
|
|
|
|
|
|
Payments Due by Period |
|
||||||||||||||||||
Contractual Obligations (1) |
Total |
|
|
Less than 1 Year |
|
|
|
1-3 years |
|
|
|
3-5 years |
|
|
More than 5 Years |
|
|||||||||
Borrowings (2) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
Credit Facility |
|
$ |
|
|
|
$ |
|
— |
|
|
$ |
|
— |
|
|
$ |
|
|
|
$ |
|
— |
|
||
2026 Notes |
|
|
|
|
|
|
|
— |
|
|
|
|
— |
|
|
|
|
|
|
|
|
— |
|
||
2027 Notes |
|
|
|
|
|
|
|
— |
|
|
|
|
— |
|
|
|
|
|
|
|
|
— |
|
||
Total Borrowings |
|
|
|
|
|
|
|
— |
|
|
|
|
— |
|
|
|
|
|
|
|
|
— |
|
||
Deferred Incentive Fees |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
Total |
|
$ |
|
|
|
$ |
|
|
|
$ |
|
|
|
$ |
|
|
|
$ |
|
|
Contingencies
The Company and RGC are not currently subject to any material legal proceedings, nor, to our knowledge, is any material legal proceeding threatened against us. From time to time, the Company or RGC may be a party to certain legal proceedings in the ordinary course of business, including proceedings relating to the enforcement of our rights under contracts with our portfolio companies. The Company's business is also subject to extensive regulation, which may result in regulatory proceedings against us. While the outcome of any such legal proceedings cannot be predicted with certainty, the Company does not expect that any such proceedings will have a material effect upon our financial condition or results of operations.
42
Off-balance Sheet Arrangements
In the normal course of business, the Company may enter into investment agreements under which it commits to make an investment in a portfolio company at some future date or over a specified period of time. These unfunded contractual commitments to provide funds to portfolio companies are not reflected on our balance sheet. The availability of such unfunded loan commitments is subject to the specific terms and conditions of each contract, which may include, among other things, portfolio company performance requirements and time-based cancellation provisions. As a result, only a portion of unfunded commitments is currently eligible to be drawn.
The Company's unfunded loan commitments to provide debt financing to its portfolio companies amounted to $
Portfolio Company |
|
Investment Type |
|
September 30, 2023 |
|
December 31, 2022 |
|
|||||
3PL Central LLC (dba Extensiv) |
|
Senior Secured Term Loan |
|
$ |
|
|
|
$ |
|
|
||
Brivo, Inc. |
|
Senior Secured Term Loan |
|
|
|
|
|
|
|
|
||
CloudPay, Inc. |
|
Senior Secured Term Loan |
|
|
|
— |
|
|
|
|
|
|
Dtex Systems, Inc. |
|
Senior Secured Term Loan |
|
|
|
— |
|
|
|
|
|
|
EBR Systems, Inc. |
|
Senior Secured Term Loan |
|
|
|
|
|
|
|
|
||
Interactions Corporation |
|
Senior Secured Term Loan |
|
|
|
|
|
|
|
|
||
Intellisite Holdings, Inc. (dba Epic IO Technologies, Inc.) |
|
Senior Secured Term Loan |
|
|
|
— |
|
|
|
|
|
|
Kin Insurance, Inc. |
|
Senior Secured Term Loan |
|
|
|
— |
|
|
|
|
|
|
Madison Reed, Inc. |
|
Senior Secured Term Loan |
|
|
|
|
|
|
|
|
||
Moximed, Inc. |
|
Senior Secured Term Loan |
|
|
|
|
|
|
|
|
||
Nalu Medical, Inc. |
|
Senior Secured Term Loan |
|
|
|
|
|
|
|
|
||
Revelle Aesthetics, Inc. |
|
Senior Secured Term Loan |
|
|
|
— |
|
|
|
|
|
|
Route 92 Medical, Inc. |
|
Senior Secured Term Loan |
|
|
|
|
|
|
|
|
||
SetPoint Medical Corporation |
|
Senior Secured Term Loan |
|
|
|
|
|
|
|
|
||
Skillshare, Inc. |
|
Senior Secured Term Loan |
|
|
|
|
|
|
|
|
||
Snagajob.com, Inc. |
|
Senior Secured Term Loan |
|
|
|
|
|
|
|
|
||
Synack, Inc. |
|
Senior Secured Term Loan |
|
|
|
|
|
|
|
|
||
Total unused commitments to extend financing |
|
|
|
$ |
|
|
|
$ |
|
|
Note 9 – Net Assets
The Company has the authority to issue
Private Common Stock Offerings
On December 1, 2017, the Company completed its initial private offering ("Initial Private Offering"), in which the Company issued
Beginning October 15, 2019 and ending September 29, 2021, the Company had completed multiple closings under its second private offering (the "Second Private Offering") and had accepted aggregate capital commitments of $
On March 31, 2020 and March 24, 2021, the Company had issued in aggregate
Initial Public Offering
On October 25, 2021, the Company closed its IPO, issuing
43
Repurchase Program
On February 24, 2022, the Board of Directors approved a repurchase program (the “Repurchase Program”) under which the Company could have repurchased up to $
Distributions
The Company intends to pay quarterly distributions to its stockholders out of assets legally available for distribution. All distributions will be paid at the discretion of the Board of Directors and will depend on the Company's earnings, financial condition, maintenance of RIC status for income tax purposes, compliance with applicable BDC regulations and such other factors as the Board of Directors may deem relevant from time to time.
For the three and nine months ended September 30, 2023, the Company declared and paid dividends in the amount of $
Dividend Reinvestment Plan
The Company maintains a dividend reinvestment plan for common stockholders (the "Dividend Reinvestment Plan"). The Company's Dividend Reinvestment Plan is administered by its transfer agent on behalf of the Company's record holders and participating brokerage firms. Brokerage firms and other financial intermediaries may decide not to participate in the Company's Dividend Reinvestment Plan but may provide a similar distribution reinvestment plan for their clients. The share requirements of the Dividend Reinvestment Plan may be satisfied through the issuance of new common shares or through open market purchases of common shares by the Company.
During the three and nine months ended September 30, 2023, the Company purchased
44
The following table summarizes the distributions declared and paid since inception through September 30, 2023:
Declaration Date |
|
Type |
|
Record Date |
|
Payment Date |
|
Amount per Share |
|
||
|
|
|
|
$ |
|
|
|||||
|
|
|
|
$ |
|
|
|||||
|
|
|
|
$ |
|
|
|||||
|
|
|
|
$ |
|
|
|||||
|
|
|
|
$ |
|
|
|||||
|
|
|
|
$ |
|
|
|||||
|
|
|
|
$ |
|
|
|||||
|
|
|
|
$ |
|
|
|||||
|
|
|
|
$ |
|
|
|||||
|
|
|
|
$ |
|
|
|||||
|
|
|
|
$ |
|
|
|||||
|
|
|
|
$ |
|
|
|||||
|
|
|
|
$ |
|
|
|||||
|
|
|
|
$ |
|
|
|||||
|
|
|
|
$ |
|
|
|||||
|
|
|
|
$ |
|
|
|||||
|
|
|
|
$ |
|
|
|||||
|
|
|
|
$ |
|
|
|||||
|
|
|
|
$ |
|
|
|||||
|
|
|
|
$ |
|
|
|||||
|
|
|
|
$ |
|
|
|||||
|
|
|
|
$ |
|
|
|||||
|
|
|
|
$ |
|
|
|||||
|
|
|
|
$ |
|
|
|||||
|
|
|
|
$ |
|
|
|||||
|
|
|
|
$ |
|
|
|||||
|
|
|
|
$ |
|
|
45
Note 10 – Income Taxes
The Company elected to be treated as a RIC under Subchapter M of the Code starting with its taxable year ended December 31, 2016. The Company currently qualifies and intends to qualify annually for the tax treatment applicable to RICs. A RIC generally is not subject to U.S. federal income taxes on distributed income and gains so long as it meets certain source-of-income and asset diversification requirements and it distributes at least
Federal income tax regulations differ from U.S. GAAP, therefore distributions in accordance with tax regulations may differ from net investment income and realized gains recognized for financial reporting purposes. Differences may be permanent or temporary in nature. Permanent differences are reclassified among capital accounts in the financial statements to reflect their appropriate tax character. Temporary differences arise when certain items of income, expense, gain or loss are recognized at some time in the future.
The following table sets forth the tax cost basis and the estimated aggregate gross unrealized gain (loss) on investments for federal income tax purposes as of and for the period ended September 30, 2023 and the year ended December 31, 2022 (in thousands):
|
|
September 30, 2023 |
|
|
December 31, 2022 |
|
||||
Tax cost on investments |
|
$ |
|
|
|
$ |
|
|
||
Change in unrealized gain on a tax basis |
|
$ |
|
|
|
$ |
|
|
||
Change in unrealized loss on a tax basis |
|
|
|
( |
) |
|
|
|
( |
) |
Net unrealized gain (loss) on a tax basis |
|
$ |
|
( |
) |
|
$ |
|
( |
) |
The Company accounts for income taxes in conformity with ASC Topic 740 — Income Taxes ("ASC 740"). ASC 740 provides guidelines for how uncertain tax positions should be recognized, measured, presented and disclosed in financial statements. ASC 740 requires the evaluation of tax positions taken or expected to be taken in the course of preparing the Company's tax returns to determine whether the tax positions are "more-likely-than-not" of being sustained by the applicable tax authority. Tax positions deemed to meet a "more-likely-than-not" threshold would be recorded as a tax benefit or expense in the current period. The Company recognizes interest and penalties, if any, related to unrecognized tax benefits as income tax expense in the Statements of Operations. There were no material uncertain income tax positions at September 30, 2023 or December 31, 2022. Although the Company files federal and state tax returns, the Company's major tax jurisdiction is federal. The previous three tax year-ends and the interim tax period since then remain subject to examination by the Internal Revenue Service.
If the Company does not distribute (or is not deemed to have distributed) each calendar year the sum of (1)
If the Company does not qualify to be treated as a RIC for any taxable year, the Company will be taxed as a regular corporation (a “C corporation”) under subchapter C of the Code for such taxable year. If the Company has previously qualified as a RIC but is subsequently unable to qualify, and certain amelioration provisions are not applicable, the Company would be subject to U.S. federal income tax on all of its taxable income (including its net capital gains) at regular corporate rates. The Company would not be able to deduct distributions to stockholders, nor would it be required to make distributions. In order to requalify as a RIC, in addition to the other requirements discussed above, the Company would be required to distribute all of its previously undistributed earnings attributable to the period it failed to qualify by the end of the first year that it intends to requalify. If the Company fails to requalify for a period greater than two taxable years, it may be subject to U.S. federal income tax at corporate tax rates on any net built-in gains with respect to certain of its assets (i.e., the excess of the aggregate gains, including items of income, over aggregate losses that would have been realized with respect to such assets if the Company had been liquidated) that it elects to recognize on requalification or when recognized over the next five years.
46
Note 11 – Financial Highlights
The following table sets forth the financial highlights for the nine months ended September 30, 2023 and 2022 (in thousands, except for per share data and ratios):
|
|
Nine Months Ended September 30, |
||||||||||
|
|
2023 |
|
2022 |
||||||||
Per Share Data(1): |
|
|
|
|
|
|
|
|
|
|
||
Net asset value at beginning of period |
|
$ |
|
|
|
|
$ |
|
|
|
||
Net investment income |
|
|
|
|
|
|
|
|
|
|
||
Net realized gain (loss) |
|
|
|
( |
) |
|
|
|
|
|
|
|
Net change in unrealized gain (loss) |
|
|
|
( |
) |
|
|
|
|
( |
) |
|
Total from investment operations |
|
|
|
|
|
|
|
|
|
|
||
Distributions |
|
|
|
( |
) |
|
|
|
|
( |
) |
|
Accretion (dilution) |
|
|
|
- |
|
|
|
|
|
|
|
|
Net asset value at end of period |
|
$ |
|
|
|
|
$ |
|
|
|
||
|
|
|
|
|
|
|
|
|
|
|
||
Ratio/Supplemental Data: |
|
|
|
|
|
|
|
|
|
|
||
Total return based on net asset value(2) |
|
|
|
( |
) |
% |
|
|
|
( |
) |
% |
Total return based on market value(3) |
|
|
|
|
% |
|
|
|
( |
) |
% |
|
Ratio of net investment income to average net assets(4)(5) |
|
|
|
|
% |
|
|
|
|
% |
||
Ratio of total operating expenses to average net assets(4)(5) |
|
|
|
|
% |
|
|
|
|
% |
||
Ratio of total operating expenses, excluding incentive fees, to average net assets(4) |
|
|
|
|
% |
|
|
|
|
% |
||
Ratio of net increase (decrease) in net assets resulting from operations to average net assets(4) |
|
|
|
|
% |
|
|
|
|
% |
||
Portfolio turnover rate(6) |
|
|
|
|
% |
|
|
|
|
% |
||
|
|
|
|
|
|
|
|
|
|
|
||
Net assets at beginning of period |
|
$ |
|
|
|
|
$ |
|
|
|
||
Net assets at end of period |
|
$ |
|
|
|
|
$ |
|
|
|
||
Weighted average net assets |
|
$ |
|
|
|
|
$ |
|
|
|
||
Weighted average shares outstanding for the period, basic |
|
|
|
|
|
|
|
|
|
|
47
Note 12 - Subsequent Events
The Company evaluated events subsequent to September 30, 2023 through November 7, 2023.
On October 6, 2023, the Company funded an investment of $
On October 6, 2023, the Company received a partial prepayment of $
On October 19, 2023, the Company funded an investment of $
On October 26, 2023, the Company funded an investment of $
On
On November 2, 2023, the Board of Directors approved a repurchase program (the “Share Repurchase Program”) under which the Company may repurchase up to $
On November 3, 2023 the Company funded an investment of $
On November 6, 2023 the Company funded an investment of $
48
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
Forward-Looking Statements
This quarterly report on Form 10‑Q contains forward-looking statements that involve substantial risks and uncertainties. Such statements involve known and unknown risks, uncertainties and other factors, and undue reliance should not be placed thereon. These forward-looking statements are not historical facts, but rather are based on current expectations, estimates and projections about us, our current and prospective portfolio investments, our industry, our beliefs and opinions, and our assumptions. Words such as “anticipates,” “expects,” “intends,” “plans,” “will,” “may,” “continue,” “believes,” “seeks,” “estimates,” “would,” “could,” “should,” “targets,” “projects,” “outlook,” “potential,” “predicts” and variations of these words and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to risks, uncertainties and other factors, some of which are beyond our control and difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements, including without limitation:
49
Although we believe the assumptions on which these forward-looking statements are based are reasonable, any of those assumptions could prove to be inaccurate, and as a result, the forward-looking statements based on those assumptions also could be inaccurate. In light of these and other uncertainties, the inclusion of a projection or forward-looking statement in this quarterly report on Form 10-Q should not be regarded as a representation by us that our plans and objectives will be achieved. These risks and uncertainties include those described or identified in “Risk Factors” in Part I, Item 1A of our annual report on Form 10-K for the year ended December 31, 2022, filed with the SEC on March 2, 2023.
We have based the forward-looking statements included in this Form 10‑Q on information available to us on the date of this Form 10‑Q, and we assume no obligation to update any such forward-looking statements. Although we undertake no obligation to revise or update any forward-looking statements, whether as a result of new information, future events or otherwise, you are advised to consult any additional disclosures that we may make directly to you or through reports that we have filed or in the future may file with the SEC, including our annual reports on Form 10‑K, quarterly reports on Form 10‑Q and current reports on Form 8‑K.
The following analysis of our financial condition and results of operations should be read in conjunction with our financial statements and the related notes thereto contained elsewhere in this quarterly report on Form 10‑Q.
Overview
Runway Growth Finance Corp. ("we," "us," "our," or the "Company"), a Maryland corporation formed on August 31, 2015, is structured as an externally managed, non-diversified closed-end management investment company. On August 18, 2021, we changed our name to "Runway Growth Finance Corp." from "Runway Growth Credit Fund Inc." We are a specialty finance company focused on providing senior secured loans to high growth-potential companies in technology, life sciences, healthcare information and services, business services, select consumer services and products and other high-growth industries. Our goal is to create significant value for our stockholders and the entrepreneurs we support by providing high growth-potential companies with hybrid debt and equity financing that is more flexible than traditional credit and less dilutive than equity. Our investment objective is to maximize our total return to our stockholders primarily through current income on our loan portfolio, and secondarily through capital gains on our warrants and other equity positions. Our offices are in Chicago, Illinois; Menlo Park, California; Dallas, Texas; and New York, New York.
We have elected to be regulated as a business development company ("BDC") under the Investment Company Act of 1940, as amended (together with the rules and regulations promulgated thereunder, the "1940 Act"). We have also elected to be treated as regulated investment company ("RIC") under Subchapter M of the Internal Revenue Code of 1986, as amended (the "Code"). While we currently qualify and intend to qualify annually to be treated as a RIC, no assurance can be provided that we will be able to maintain our tax treatment as a RIC. If we fail to qualify for tax treatment as a RIC for any taxable year, we will be subject to U.S. federal income tax at corporate rates on any net taxable income for such year. As a BDC and a RIC, we are required to comply with various regulatory requirements, such as the requirement to invest at least 70% of our assets in “qualifying assets,” source-of-income limitations, asset diversification requirements, and the requirement to distribute annually at least 90% of our investment company taxable income and net tax-exempt interest.
We are an “emerging growth company,” as defined in the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”). We will remain an emerging growth company until the last day of our fiscal year following the fifth anniversary of our IPO (December 31, 2026), or until the earliest of (i) the last day of the first fiscal year in which we have total annual gross revenue of $1.235 billion or more, (ii) December 31 of the fiscal year in which we become a “large accelerated filer” as defined in Rule 12b-2 under the Securities Exchange Act of 1934, as amended (together with the rules and regulations promulgated thereunder, the “Exchange Act”), (which would occur if the market value of our common stock held by non-affiliates exceeds $700.0 million, measured as of the last business day of our most recently completed second fiscal quarter, and we have been publicly reporting for at least 12 months), or (iii) the date on which we have issued more than $1.0 billion in non-convertible debt during the preceding three-year period. For so long as we remain an emerging growth company under the JOBS Act, we will be subject to reduced public company reporting requirements.
50
We are externally managed by Runway Growth Capital LLC ("RGC"), an investment adviser that has registered with the SEC under the Investment Advisers Act of 1940, as amended. The Administrator, a wholly-owned subsidiary of RGC, provides all the administrative services necessary for us to operate.
On August 10, 2020, we, RGC, and certain other funds and accounts sponsored or managed by RGC and/or its affiliates were granted an order (the “Order”), amended on August 30, 2022, that permits us greater flexibility than the 1940 Act permits to negotiate the terms of co-investments if our Board of Directors determines that it would be advantageous for us to co-invest with other accounts sponsored or managed by RGC or its affiliates in a manner consistent with our investment objective, positions, policies, strategies and restrictions as well as regulatory requirements and other pertinent factors. We believe that the ability to co-invest with similar investment structures and accounts sponsored or managed by RGC or its affiliates will provide additional investment opportunities and the ability to achieve greater diversification. Under the terms of the Order, a majority of our independent directors are required to make certain determinations in connection with a co-investment transaction, including that (1) the terms of the proposed transaction are reasonable and fair to us and our stockholders and do not involve overreaching of us or our stockholders on the part of any person concerned and (2) the transaction is consistent with the interests of our and is consistent with our investment strategies and policies.
On August 30, 2022, we received an amendment to our existing Order to permit us to, subject to the satisfaction of certain conditions, co-invest in our existing portfolio companies with certain affiliates that are private funds even if such other funds had not previously invested in such existing portfolio company. Without this Order, such affiliated funds that are private funds would not be able to participate in such co-investments with us unless the affiliated funds had previously acquired securities of the portfolio company in a co-investment transaction with us.
Portfolio Composition and Investment Activity
Portfolio Composition
At September 30, 2023, we had investments in 50 portfolio companies, representing 20 companies in which we held loan and warrant investments, three companies in which we held loan investments and shares of common stock, preferred stock, or a combination with warrants, five companies in which we held a loan investment only, 17 companies in which we held warrant investments only, and five companies in which we held shares of common stock or preferred stock only, or a combination with warrants. At December 31, 2022, we had investments in 49 portfolio companies, representing 28 companies in which we held loan and warrant investments, one companies in which we held loan investments and shares of common, preferred stock, or a combination with warrants, six companies in which we held a loan investment only, nine companies in which we held warrant investments only, and five companies in which we held shares of common or preferred stock only, or a combination with warrants.
The following table shows the fair value of our investments, by asset class, as of September 30, 2023 and December 31, 2022 (in thousands):
|
|
September 30, 2023 |
|
December 31, 2022 |
||||||||||||||||||||||||||||
Investments |
|
Cost |
|
|
Fair Value |
|
|
|
% of Total Portfolio |
|
Cost |
|
|
Fair Value |
|
|
|
% of Total Portfolio |
||||||||||||||
Portfolio Investments |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Senior Secured Term Loans |
|
$ |
|
964,734 |
|
|
$ |
|
947,515 |
|
|
|
|
93.73 |
|
% |
|
$ |
|
1,096,724 |
|
|
$ |
|
1,080,121 |
|
|
|
|
95.90 |
|
% |
Second Lien Term Loans |
|
|
|
14,178 |
|
|
|
|
14,178 |
|
|
|
|
1.40 |
|
|
|
|
|
13,654 |
|
|
|
|
13,654 |
|
|
|
|
1.21 |
|
|
Preferred Stocks |
|
|
|
37,382 |
|
|
|
|
33,258 |
|
|
|
|
3.29 |
|
|
|
|
|
12,382 |
|
|
|
|
12,682 |
|
|
|
|
1.13 |
|
|
Common Stocks |
|
|
|
9,125 |
|
|
|
|
1,963 |
|
|
|
|
0.19 |
|
|
|
|
|
8,715 |
|
|
|
|
3,097 |
|
|
|
|
0.27 |
|
|
Warrants |
|
|
|
19,455 |
|
|
|
|
14,013 |
|
|
|
|
1.39 |
|
|
|
|
|
19,127 |
|
|
|
|
16,755 |
|
|
|
|
1.49 |
|
|
Total Investments |
|
$ |
|
1,044,874 |
|
|
$ |
|
1,010,927 |
|
|
|
|
100.00 |
|
% |
|
$ |
|
1,150,602 |
|
|
$ |
|
1,126,309 |
|
|
|
|
100.00 |
|
% |
For the three and nine months ended September 30, 2023, our debt investment portfolio had a dollar-weighted annualized yield of 18.3% and 16.0%, respectively. For the three and nine months ended September 30, 2022, our debt investment portfolio had a dollar-weighted annualized yield of 14.4% and 13.5%, respectively. We calculate the yield on dollar-weighted debt investments for any period measured as (1) total related investment income during the period divided by (2) the daily average of the fair value of debt investments outstanding during the period. As of September 30, 2023, our debt investments had a dollar-weighted average outstanding term of 57 months at origination and a dollar-weighted average remaining term of 38 months, or approximately 3.2 years. As of September 30, 2023, substantially all of our debt investments had committed principal amounts of between $6.0 million and $85.0 million, repayment terms of between 34 months and 82 months and pay cash interest at annual interest rates of between 7.1% and 15.7%.
51
The following table shows our dollar-weighted annualized yield by investment type for the three and nine months ended September 30, 2023 and 2022:
|
|
Fair Value(1) |
|
Cost(2) |
||||||||||||||||||||||||||||||||||||
|
|
Three Months Ended September 30, |
|
Nine Months Ended September 30, |
|
Three Months Ended September 30, |
|
Nine Months Ended September 30, |
||||||||||||||||||||||||||||||||
|
|
2023 |
|
2022 |
|
2023 |
|
2022 |
|
2023 |
|
2022 |
|
2023 |
|
2022 |
||||||||||||||||||||||||
Investment type: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
Debt investments |
|
|
18.28 |
|
% |
|
|
14.43 |
|
% |
|
|
16.04 |
|
% |
|
|
13.49 |
|
% |
|
|
18.02 |
|
% |
|
|
14.10 |
|
% |
|
|
15.80 |
|
% |
|
|
13.30 |
|
% |
Equity interest |
|
|
2.52 |
|
% |
|
|
3.64 |
|
% |
|
|
2.70 |
|
% |
|
|
3.36 |
|
% |
|
|
1.97 |
|
% |
|
|
3.16 |
|
% |
|
|
2.17 |
|
% |
|
|
3.41 |
|
% |
All investments |
|
|
17.48 |
|
% |
|
|
13.95 |
|
% |
|
|
15.45 |
|
% |
|
|
12.94 |
|
% |
|
|
17.00 |
|
% |
|
|
13.55 |
|
% |
|
|
15.07 |
|
% |
|
|
12.77 |
|
% |
Investment Activity
The value of our investment portfolio will change over time due to changes in the fair value of our underlying investments, as well as changes in the composition of our portfolio resulting from purchases of new and follow-on investments as well as repayments and sales of existing investments. During the nine months ended September 30, 2023, the Company funded 19.8 million in one new portfolio company, and $85.7 million in 11 existing portfolio companies, net of upfront loan origination fees. The Company also received $225.7 million in loan prepayments from 10 portfolio companies and $7.0 million in scheduled principal payments from two portfolio companies. There were no proceeds from the termination of warrants, sale of preferred stock, and sale of common stock. During the nine months ended September 30, 2022, the Company funded $210.4 million in eight new portfolio companies and $182.4 million in ten existing portfolio companies, net of upfront loan origination fees. The Company also received $135.9 million in loan prepayments from six portfolio companies and $7.3 million in scheduled principal payments from two portfolio companies. There were $7.2 million in proceeds from the termination of warrants, sale of preferred stock, and sale of common stock.
Portfolio Reconciliation
The following is a reconciliation of our investment portfolio, including U.S. Treasury Bills, for the nine months ended September 30, 2023 and 2022 (in thousands):
|
|
|
|
|
|
Nine Months Ended September 30, |
|
||||||
|
|
|
|
|
2023 |
|
|
2022 |
|
||||
Beginning investment portfolio |
|
$ |
|
1,126,309 |
|
|
$ |
|
729,516 |
|
|||
Purchases of investments |
|
|
|
105,527 |
|
|
|
|
392,820 |
|
|||
Purchases of U.S. Treasury Bills |
|
|
|
34,974 |
|
|
|
|
— |
|
|||
PIK interest |
|
|
|
15,334 |
|
|
|
|
6,345 |
|
|||
Sales and prepayments of investments |
|
|
|
(225,671 |
) |
|
|
|
(143,144 |
) |
|||
Scheduled principal payments of investments |
|
|
|
(7,046 |
) |
|
|
|
(7,266 |
) |
|||
Sales and maturities of U.S. Treasury Bills(1) |
|
|
|
(35,000 |
) |
|
|
|
(45,000 |
) |
|||
Net realized gain (loss) on investments |
|
|
|
(1,178 |
) |
|
|
|
939 |
|
|||
Net change in unrealized gain (loss) on investments |
|
|
|
(9,654 |
) |
|
|
|
(28,617 |
) |
|||
Amortization of fixed income premiums or accretion of discounts |
|
|
|
7,332 |
|
|
|
|
4,576 |
|
|||
Ending investment portfolio |
|
$ |
|
1,010,927 |
|
|
$ |
|
910,169 |
|
52
Asset Quality
In addition to various risk management and monitoring tools, RGC uses an investment rating system to characterize and monitor the quality of our debt investment portfolio. Equity securities and Treasury Bills are not graded. This debt investment rating system uses a five-level numeric scale. The following is a description of the conditions associated with each investment rating:
Investment |
|
Rating Definition |
|
|
|
1 |
|
Performing above plan and/or strong enterprise profile, value, financial performance/coverage. Maintaining full covenant and payment compliance as agreed. |
2 |
|
Performing at or reasonably close to plan. Acceptable business prospects, enterprise value, financial coverage. Maintaining key covenant and payment compliance as agreed. All new loans are initially graded Category 2. |
3 |
|
Performing below plan of record. Potential elements of concern over performance, trends and business outlook. Loan-to-value remains adequate. Potential key covenant non-compliance. Full payment compliance. |
4 |
|
Performing materially below plan. Non-compliant with material financial covenants. Payment default/deferral could result without corrective action. Requires close monitoring. Business prospects, enterprise value and collateral coverage declining. These investments may be in workout, and there is a possibility of loss of return but no loss of principal is expected. |
5 |
|
Going concern nature in question. Substantial decline in enterprise value and all coverages. Covenant and payment default imminent if not currently present. Investments are nearly always in workout. May experience partial and/or full loss. |
The following table shows the investment ratings of our debt investments at fair value as of September 30, 2023 and December 31, 2022 (dollars in thousands):
|
|
September 30, 2023 |
|
|
December 31, 2022 |
||||||||||||||
Investment Rating |
|
Fair Value |
|
|
% of Total Portfolio |
|
Number of Portfolio Companies |
|
|
Fair Value |
|
|
% of Total Portfolio |
|
Number of Portfolio Companies |
||||
1 |
|
$ |
— |
|
|
— |
% |
|
— |
|
|
$ |
— |
|
|
— |
% |
|
— |
2 |
|
|
779,670 |
|
|
77.13 |
|
|
20 |
|
|
|
1,006,247 |
|
|
89.34 |
|
|
30 |
3 |
|
|
166,346 |
|
|
16.45 |
|
|
6 |
|
|
|
78,238 |
|
|
6.95 |
|
|
4 |
4 |
|
|
4,064 |
|
|
0.40 |
|
|
1 |
|
|
|
— |
|
|
- |
|
|
— |
5 |
|
|
11,613 |
|
|
1.15 |
|
|
1 |
|
|
|
9,290 |
|
|
0.82 |
|
|
1 |
|
|
$ |
961,693 |
|
|
95.13 |
% |
|
28 |
|
|
$ |
1,093,775 |
|
|
97.11 |
% |
|
35 |
Loans and Debt Securities on Non-Accrual Status
Generally, when interest and/or principal payments on a loan become past due, or if we otherwise do not expect the borrower to be able to service its debt and other obligations, we will place the loan on non-accrual status and will cease recognizing interest income on that loan for financial reporting purposes until all principal and interest have been brought current through payment or due to a restructuring such that the interest income is deemed to be collectible. As of September 30, 2023 and December 31, 2022, we have not written off any accrued and uncollected PIK interest. As of September 30, 2023, we had one loan to Pivot3, Inc. on non-accrual status. The loan, with a cost basis of $18.0 million and a fair value of $11.6 million, represents 1.1% of the total investment portfolio. From being placed on non-accrual status through September 30, 2023, cumulative interest of $6.0 million would be receivable and $0.3 million OID would be accreted into the cost basis, for a total of $6.3 million not recorded in Interest income from control investments on the Statements of Operations. As of December 31, 2022, we had one loan to Pivot3, Inc. on non-accrual status. The loan, with a cost basis of $19.2 million and a fair market value of $9.3 million represents 0.8% of the total investment portfolio. From being placed on non-accrual status through December 31, 2022, cumulative interest of $3.6 million would be payable and $0.3 million OID would be accreted into the cost basis, for a total of $3.9 million not recorded in Interest income from control investments on the Statements of Operations.
53
Results of Operations
An important measure of our financial performance is net increase/(decrease) in net assets resulting from operations, which includes net investment income/(loss), net realized gain/(loss) and net unrealized gain/(loss). Net investment income/(loss) is the difference between our income from interest, dividends, fees and other investment income and our operating expenses, including interest on borrowed funds. Net realized gain/(loss) on investments is the difference between the proceeds received from dispositions of portfolio investments and their amortized cost. Net unrealized gain/(loss) on investments is the net change in the fair value of our investment portfolio.
Comparison of the Three and Nine Months Ended September 30, 2023 and 2022
The following table is a comparison of the results of our operations for the three and nine months ended September 30, 2023 and 2022 (dollars in thousands):
|
|
Three Months Ended September 30, |
|
|
|
Nine Months Ended September 30, |
|
||||||||||||||||||||||||||||||||||
|
|
2023 |
|
|
2022 |
|
|
|
2023 |
|
|
2022 |
|
||||||||||||||||||||||||||||
|
|
Total |
|
|
Per Share(1) |
|
|
Total |
|
|
Per Share(1) |
|
|
|
Total |
|
|
Per Share(1) |
|
|
Total |
|
|
Per Share(1) |
|
||||||||||||||||
Investment income |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
Interest, fee and dividend income |
|
$ |
|
43,552 |
|
|
$ |
|
1.07 |
|
|
$ |
|
27,036 |
|
|
$ |
|
0.66 |
|
|
|
$ |
|
124,632 |
|
|
$ |
|
3.08 |
|
|
$ |
|
71,293 |
|
|
$ |
|
1.73 |
|
Other income |
|
|
|
227 |
|
|
|
|
0.01 |
|
|
|
|
1 |
|
|
|
|
- |
|
|
|
|
|
352 |
|
|
|
|
0.01 |
|
|
|
|
1 |
|
|
|
|
— |
|
Total investment income |
|
|
|
43,779 |
|
|
|
|
1.08 |
|
|
|
|
27,037 |
|
|
|
|
0.66 |
|
|
|
|
|
124,984 |
|
|
|
|
3.09 |
|
|
|
|
71,294 |
|
|
|
|
1.73 |
|
Operating expenses |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
Management fees |
|
|
|
4,302 |
|
|
|
|
0.11 |
|
|
|
|
3,066 |
|
|
|
|
0.07 |
|
|
|
|
|
12,598 |
|
|
|
|
0.31 |
|
|
|
|
8,488 |
|
|
|
|
0.20 |
|
Incentive fees |
|
|
|
5,511 |
|
|
|
|
0.13 |
|
|
|
|
3,626 |
|
|
|
|
0.09 |
|
|
|
|
|
14,994 |
|
|
|
|
0.37 |
|
|
|
|
8,591 |
|
|
|
|
0.21 |
|
Interest and other debt financing expenses |
|
|
|
10,442 |
|
|
|
|
0.26 |
|
|
|
|
4,382 |
|
|
|
|
0.10 |
|
|
|
|
|
32,772 |
|
|
|
|
0.81 |
|
|
|
|
8,297 |
|
|
|
|
0.20 |
|
Professional fees |
|
|
|
466 |
|
|
|
|
0.01 |
|
|
|
|
482 |
|
|
|
|
0.01 |
|
|
|
|
|
1,504 |
|
|
|
|
0.04 |
|
|
|
|
1,677 |
|
|
|
|
0.04 |
|
Administration agreement expenses |
|
|
|
449 |
|
|
|
|
0.01 |
|
|
|
|
459 |
|
|
|
|
0.01 |
|
|
|
|
|
1,647 |
|
|
|
|
0.04 |
|
|
|
|
1,331 |
|
|
|
|
0.03 |
|
Insurance expense |
|
|
|
269 |
|
|
|
|
0.01 |
|
|
|
|
268 |
|
|
|
|
0.01 |
|
|
|
|
|
805 |
|
|
|
|
0.02 |
|
|
|
|
806 |
|
|
|
|
0.02 |
|
Tax expense |
|
|
|
— |
|
|
|
|
— |
|
|
|
|
— |
|
|
|
|
- |
|
|
|
|
|
50 |
|
|
|
|
— |
|
|
|
|
1 |
|
|
|
|
— |
|
Other expenses |
|
|
|
304 |
|
|
|
|
0.01 |
|
|
|
|
256 |
|
|
|
|
0.01 |
|
|
|
|
|
656 |
|
|
|
|
0.02 |
|
|
|
|
667 |
|
|
|
|
0.02 |
|
Total operating expenses |
|
|
|
21,743 |
|
|
|
|
0.54 |
|
|
|
|
12,539 |
|
|
|
|
0.30 |
|
|
|
|
|
65,026 |
|
|
|
|
1.61 |
|
|
|
|
29,858 |
|
|
|
|
0.72 |
|
Net investment income |
|
|
|
22,036 |
|
|
|
|
0.54 |
|
|
|
|
14,498 |
|
|
|
|
0.36 |
|
|
|
|
|
59,958 |
|
|
|
|
1.48 |
|
|
|
|
41,436 |
|
|
|
|
1.01 |
|
Realized gain (loss) on investments |
|
|
|
— |
|
|
|
|
— |
|
|
|
|
407 |
|
|
|
|
0.01 |
|
|
|
|
|
(1,178 |
) |
|
|
|
(0.03 |
) |
|
|
|
939 |
|
|
|
|
0.02 |
|
Net change in unrealized gain (loss) on investments |
|
|
|
(7,214 |
) |
|
|
|
(0.17 |
) |
|
|
|
(3,183 |
) |
|
|
|
(0.08 |
) |
|
|
|
|
(9,654 |
) |
|
|
|
(0.24 |
) |
|
|
|
(28,617 |
) |
|
|
|
(0.70 |
) |
Net increase (decrease) in net assets resulting from operations |
|
$ |
|
14,822 |
|
|
$ |
|
0.37 |
|
|
$ |
|
11,722 |
|
|
$ |
|
0.29 |
|
|
|
$ |
|
49,126 |
|
|
$ |
|
1.21 |
|
|
$ |
|
13,758 |
|
|
$ |
|
0.33 |
|
Investment Income
Our investment objective is to maximize total return to our stockholders primarily through current income on our loan portfolio, and secondarily through capital gain on our warrants and other equity positions. We intend to achieve our investment objective by investing in high growth-potential, private companies. We typically invest in senior secured loans that generally fall into two strategies: Sponsored Growth Lending and Non-Sponsored Growth Lending. We generally receive warrants and/or other equity from our investments. We expect our investments in loans will generally range from between $10.0 million to $100.0 million, and the upper end of this range may increase as we raise additional capital.
We generate revenue in the form of interest on the debt securities that we hold and distributions and capital gains on other interests that we acquire in our portfolio companies. We expect that the debt we invest in will generally have stated terms of 36 to 60 months. Interest on debt securities is generally payable monthly, primarily based on a floating rate index, and subject to certain floors determined by market rates at the time the investment is made. In some cases, some of our investments may provide for deferred interest payments or PIK interest. The principal amount of the debt securities and any accrued but unpaid interest will become due at the maturity date. Any original issue discount ("OID") or market discount or premium will be capitalized, and we will accrete or amortize such amounts as interest income. We record prepayment fees on debt investments as fee income. Dividend income, if any, will be recognized on an accrual basis to the extent that we expect to collect such amounts.
54
Investment income for the three months ended September 30, 2023 and 2022 was $43.8 million and $27.0 million, respectively, and includes non-recurring income of $5.6 million and $0.4 million, respectively. Non-recurring income includes, but is not limited to, acceleration of unaccreted OID, prepayment fees and amendment fees. The increase in investment income for the three months ended September 30, 2023 compared to the three months ended September 30, 2022 was primarily due to increased interest income driven by our deployment of capital and increased market interest rates.
Investment income for the nine months ended September 30, 2023 and 2022 was $125.0 million and $71.3 million, respectively, and includes non-recurring income of $9.0 million and $2.9 million, respectively. Non-recurring income includes, but is not limited to, acceleration of unaccreted OID, prepayment fees and amendment fees. The increase in investment income for the nine months ended September 30, 2023 compared to the nine months ended September 30, 2022 was primarily due to increased interest income driven by our deployment of capital and increased market interest rates.
Operating Expenses
Our primary operating expenses include the payment of fees to RGC under the Advisory Agreement, our allocable portion of overhead expenses under the Administration Agreement, professional fees, and other operating costs described below. We bear all other out-of-pocket costs and expenses of our operations and transactions, including those relating to:
Operating expenses for the three months ended September 30, 2023 and 2022 were $21.7 million and $12.5 million, respectively. Operating expenses increased for the three months ended September 30, 2023 from the three months ended September 30, 2022 primarily
55
due to an increase in interest expense as a result of increased leverage, performance-based incentive fees, and management fees. Operating expenses for the three months ended September 30, 2023 and 2022 were $0.54 and $0.30 per share, respectively.
Operating expenses for the nine months ended September 30, 2023 and 2022 were $65.0 million and $29.9 million, respectively. Operating expenses increased for the nine months ended September 30, 2023 from the nine months ended September 30, 2022 primarily due to an increase in interest expense as a result of increased leverage, performance-based incentive fees, and management fees. Operating expenses for the nine months ended September 30, 2023 and 2022 were $1.61 and $0.72 per share, respectively.
Management fees for the three months ended September 30, 2023 and 2022 were $4.3 million and $3.1 million, respectively. Management fees increased for the three months ended September 30, 2023 from the three months ended September 30, 2022 primarily due to an increase in gross assets, offset by a decrease in the base management rate from 1.6% to 1.5% per annum.
Management fees for the nine months ended September 30, 2023 and 2022 were $12.6 million and $8.5 million, respectively. Management fees increased for the nine months ended September 30, 2023 from the nine months ended September 30, 2022 primarily due to an increase in gross assets, offset by a decrease in the base management rate from 1.6% to 1.5% per annum.
Incentive fees for the three months ended September 30, 2023 and 2022 were $5.5 million and $3.6 million, respectively. Incentive fees increased for the three months ended September 30, 2023 from the three months ended September 30, 2022 primarily due to an increase in net investment income. For the three months ended September 30, 2023, $4.0 million of the incentive fees were payable in cash, and $1.5 million were deferred and accrued. For the three months ended September 30, 2022, $3.2 million of the incentive fees were payable in cash, and $0.4 million were deferred and accrued. Incentive fees related to PIK or deferred interest are accrued and payment is deferred until such interest is collected in cash. Incentive fees for the three months ended September 30, 2023 and 2022 were $0.13 and $0.09 per share, respectively.
Incentive fees for the nine months ended September 30, 2023 and 2022 were $15.0 million and $8.6 million, respectively. Incentive fees increased for the nine months ended September 30, 2023 from the nine months ended September 30, 2022 primarily due to an increase in net investment income. For the nine months ended September 30, 2023, $10.9 million of the incentive fees were payable in cash, and $4.1 million were deferred and accrued. For the nine months ended September 30, 2022, $7.3 million of the incentive fees were payable in cash, and $1.3 million were deferred and accrued. Incentive fees related to PIK or deferred interest are accrued and payment is deferred until such interest is collected in cash. Incentive fees for the nine months ended September 30, 2023 and 2022 were $0.37 and $0.21 per share, respectively.
Net Investment Income
Net investment income for the three months ended September 30, 2023 and 2022 was $22.0 million and $14.5 million, respectively. Net investment income increased for the three months ended September 30, 2023 from the three months ended September 30, 2022 was primarily due to rising interest rates on our investments, partially offset by an increase in interest expense, performance-based incentive fees, and management fees. Net investment income for the three months ended September 30, 2023 and 2022 was $0.54 and $0.36 per share, respectively.
Net investment income for the nine months ended September 30, 2023 and 2022 was $60.0 million and $41.4 million, respectively. Net investment income increased for the nine months ended September 30, 2023 from the nine months ended September 30, 2022 primarily due to rising interest rates partially offset by an increase in performance-based incentive fees, management fees, debt financing fees, and interest expense. Net investment income for the nine months ended September 30, 2023 and 2022 was $1.48 and $1.01 per share, respectively.
Net Realized Gain (Loss) on Investments
There were no net realized gains (losses) on investments for the three months ended September 30, 2023. The net realized gain on investments of $0.4 million for the three months ended September 30, 2022 was primarily due to the gain on a portion of our investment in the common stock of Brilliant Earth Group, Inc and partially offset by a loss on our investment in the warrants in Aspen Group Inc.
Net realized losses on investments of $1.2 million for the nine months ended September 30, 2023 was attributable to our investments in CareCloud, Inc. and Gynesonics, Inc warrants. The net realized gain on investments of $0.9 million for the nine months ended September 30, 2022 was primarily due to the gain on a portion of our investment in the common stock of Brilliant Earth Group, Inc. partially offset by the loss on our investments in the preferred stock and warrants in CareCloud, Inc. and Aspen Group Inc.
56
Net Change in Unrealized Gain (Loss) on Investments
Net change in unrealized loss on investments of $7.2 million for the three months ended September 30, 2023 was primarily due to a decrease in the fair value of our preferred stock investment in CareCloud, Inc. and our senior secured loans to Snagajob.com, Inc. and Fiscal Note, Inc., as well as a release of unrealized gain on the senior secured loans to Allurion Technologies, Inc. The net change in unrealized loss on investments of $3.2 million for the three months ended September 30, 2022 was primarily due to a release in the unrealized gain on Fiscal Note warrants and decreases in the fair value of our investment in the senior secured loan to Pivot3, Inc.
Net change in unrealized loss on investments of $9.7 million for the nine months ended September 30, 2023 was primarily due to decreases in the fair value of our preferred stock investment in Gynesonics, Inc. and senior secured loans to Gynesonics, Inc. and Snagajob.com, Inc. The net change in unrealized loss on investments of $28.6 million for the nine months ended September 30, 2022 was primarily due to decreases in the fair value of our investments in the senior secured loan to Pivot3, Inc., common stock of Brilliant Earth Group, Inc., and common stock of Coginiti Corp.
Net Increase (Decrease) in Net Assets Resulting from Operations
We had a net increase in net assets resulting from operations of $14.8 million for the three months ended September 30, 2023, as compared to a net decrease in net assets resulting from operations of $11.7 million for the three months ended September 30, 2022. The net increase in net assets resulting from operations for the three months ended September 30, 2023 from the three months ended September 30, 2022 was primarily due to the comparative net change in unrealized gain (loss), as well as an increase in net investment income for the three months ended September 30, 2023.
We had a net increase in net assets resulting from operations of $49.1 million and $13.8 million for the nine months ended September 30, 2023 and 2022, respectively. The net increase in net assets resulting from operations for the nine months ended September 30, 2023 from the nine months ended September 30, 2022 was primarily due to the comparative net change in unrealized gain (loss), as well as an increase in net investment income for the nine months ended September 30, 2023.
Financial Condition, Liquidity, Capital Resources and Obligations
Our liquidity and capital resources are derived from net proceeds from the offering of our securities, debt borrowings and cash flows from operations, including investment sales and repayments, and income earned. We have used, and expect to continue to use, our debt and the proceeds from the turnover of our portfolio and from public and private offerings of securities to finance our investment objectives. We expect that we may also generate cash from any financing arrangements we may enter into in the future and any future offerings of our equity or debt securities. Financing arrangements may come in the form of borrowings from banks or issuances of senior securities, which may be secured or unsecured, through registered offerings or private placements. Our primary use of funds is to make investments in eligible portfolio companies, pay our operating expenses and make distributions to holders of our common stock.
During the nine months ended September 30, 2023, we principally funded our operations from (i) cash receipts from interest, dividend, and fee income from our investment portfolio and (ii) cash proceeds from the realization of portfolio investments through the repayments of debt investments and the sale of debt and equity investments.
During the nine months ended September 30, 2023, our operating activities provided $174.1 million of cash and cash equivalents, compared to $164.1 million used during the nine months ended September 30, 2022, respectively. The $338.2 million increase in cash provided by operating activities was primarily due to a $252.3 million decrease in purchases of investments and U.S. Treasury Bills and a $72.3 million increase in sales and repayments of investments and U.S. Treasury Bills.
During the nine months ended September 30, 2023, our financing activities used $164.9 million of cash, compared to $165.2 million provided by financing activities during the nine months ended September 30, 2022 . The $330.1 million increase in cash flows used in financing activities was primarily due to decreased net borrowing activity of $373.5 million and increased dividend distributions of $17.7 million, offset by decreased cash used in reverse repurchase agreements of $44.8 million.
As of September 30, 2023, our net assets totaled $570.5 million, with a net asset value per share of $14.08. We intend to continue to operate in order to generate cash flows from operations, including income earned from investments in our portfolio companies. Our primary use of funds will be investments in portfolio companies and cash distributions to holders of our common stock.
57
Available Liquidity and Capital Resources
As of September 30, 2023, we had $311.9 million in available liquidity, including $14.9 million in cash and cash equivalents, and approximately $297.0 million available under our Credit Facility, subject to borrowing base capacity. As of September 30, 2023, we had $203.0 million of secured debt outstanding under our Credit Facility, which are floating interest rate obligations and $247.3 million of unsecured debt outstanding under 2026 and 2027 Notes, which are all fixed interest rate debt obligations. Refer to "Note 7 – Borrowings" to our financial statements in Part I, Item 1 of this Form 10-Q for additional discussion of our debt obligations.
Pursuant to the 1940 Act, we are permitted to incur borrowings, issue debt securities, or issue preferred stock unless, immediately after the borrowings or issuance, the ratio of total assets (less total liabilities other than indebtedness) to total indebtedness plus preferred stock is at least 150% (at least 200% prior to June 17, 2022). As of September 30, 2023 and December 31, 2022, our asset coverage ratio was 227% and 203%, respectively.
As detailed above, our diverse and well-structured balance sheet is designed to provide a long-term focused and sustainable investment platform. Currently, we believe we have sufficient liquidity to support our near-term capital requirements.
Commitments and Obligations
Our significant contractual payment obligations relate to our borrowings and deferred incentive fees. As of September 30, 2023, we had $450.3 million of debt outstanding, none of which was due within the next year, $228.0 million within 1 to 3 years, and $222.3 million beyond 3 years. As of September 30, 2023, we had $8.4 million of deferred incentive fees, $2.6 million of which was due within the next year, $3.1 million within 1 to 3 years, and $2.7 million beyond 3 years.
In addition to our on-balance sheet contractual obligations, in the normal course of business, we have future cash requirements related to our financial instruments with off-balance sheet risk. These consist of unfunded loan commitments to extend credit, in the form of loans, to our portfolio companies. Unfunded loan commitments to provide funds to portfolio companies are not reflected on our balance sheet.
Our unfunded loan commitments may be significant from time to time. As of September 30, 2023, we had $203.5 million in unfunded loan commitments to provide debt financing to its portfolio companies. The availability of unfunded loan commitments are dependent upon the portfolio company reaching certain performance milestones and time-based cancellation provisions before the loan commitment becomes available. Furthermore, our credit agreements generally contain customary lending provisions which allow us relief from funding obligations for previously made unfunded commitments in instances where the underlying company experiences materially adverse events that affect the financial condition or business outlook for the company. These commitments will be subject to the same underwriting and ongoing portfolio maintenance as are the on-balance sheet financial instruments that we hold. Since these commitments may expire without being drawn upon, the total commitment amount does not necessarily represent future cash requirements. We maintain sufficient liquidity (through cash on hand and available borrowings under the Credit Facility) to fund such unfunded loan commitments should the need arise. As of September 30, 2023, we had approximately $75.1 million of available unfunded commitments eligible to be drawn based on achieved milestones. Refer to “Note 8 – Commitments and Contingencies” of our financial statements in Part I, Item 1 of this Form 10-Q for a summary of unfunded loan commitments by portfolio company as of September 30, 2023.
The fair value of our unfunded commitments is considered to be immaterial as the yield determined at the time of underwriting is expected to be materially consistent with the yield upon funding, given that interest rates are generally pegged to market indices and given the existence of milestones, conditions and/or obligations embedded in the borrowing agreements.
58
Distributions
To the extent that we have funds available, we intend to make quarterly distributions to our stockholders. Our stockholder distributions, if any, will be determined by our Board of Directors. Any distribution to our stockholders will be declared out of assets legally available for distribution. We anticipate that distributions will be paid from income primarily generated by interest and dividend income earned on investments made by us.
During the three and nine months ended September 30, 2023, we declared and paid dividends in the amount of $18.2 million and $54.7 million, respectively, of which $17.5 million and $52.4 million, respectively, were distributed in cash and the remainder distributed in shares to stockholders pursuant to our Dividend Reinvestment Plan. For the three and nine months ended September 30, 2022, we declared dividends in the amount of $13.5 million, and $37.0 million of which $12.8 million and $26.7 million, respectively, were distributed in cash and the remainder distributed in shares to stockholders pursuant to our Dividend Reinvestment Plan.
The timing and amount of our distributions, if any, will be determined by our Board of Directors and will be declared out of assets legally available for distribution. Refer to "Note 9 – Net Assets" of our financial statements in Part I, Item 1 of this Form 10-Q for a summary of the distributions declared and paid since inception.
Critical Accounting Estimates
The preparation of the financial statements and related disclosures in conformity with U.S. GAAP requires our management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and revenues and expenses during the period reports. Actual results could materially differ from those estimates. For a description of our critical accounting policies, including those related to the valuation of investments and our election to be treated, and intent to qualify annually, as a RIC refer to “Note 2 – Summary of Significant Accounting Policies” to our financial statements in Part I, Item 1 of this Form 10-Q. We consider the most significant accounting policies to be those related to our Fair Value Measurements and Income Taxes.
Item 3. Quantitative and Qualitative Disclosures about Market Risk
We commenced investment activities in portfolio securities during the quarter ended June 30, 2017 and commenced investment activities in U.S. Treasury Bills during the quarter ended December 31, 2016.
We are subject to financial market risk, including changes in the valuations of our investment portfolio. Market risk includes risks that arise from changes in interest rates, commodity prices, equity prices and other market changes that affect market sensitive instruments. The prices of securities held by us may decline in response to certain events, including those directly involving the companies we invest in; conditions affecting the general economy; overall market changes; legislative reform; local, regional, national or global political, social or economic instability; and interest rate fluctuations. Uncertainty with respect to the ongoing economic effects of the COVID‑19 pandemic has introduced significant volatility in the financial markets, and the effects of this volatility could materially impact our market risks.
Valuation Risk
Our investments may not have a readily available market price, and we value these investments at fair value as determined in good faith by our Board of Directors in accordance with our valuation policy. There is no single standard for determining fair value in good faith. As a result, determining fair value requires that judgment be applied to the specific facts and circumstances of each portfolio investment while employing a consistently applied valuation process for the types of investments we make. Due to the inherent uncertainty of determining the fair value of investments that do not have a readily available market value, the fair value of our investments may fluctuate from period to period. Because of the inherent uncertainty of valuation, these estimated values may differ significantly from the values that would have been used had a ready market for the investments existed, and it is possible that the difference could be material.
Interest Rate Risk
We are subject to financial market risks, including changes in interest rates. Interest rate risk is defined as the sensitivity of our current and future earnings to interest rate volatility, variability of spread relationships, the difference in re-pricing intervals between our assets and liabilities and the effect that interest rates may have on our cash flows. Changes in interest rates may affect both our cost of funding
59
and our interest income from portfolio investments, and cash and cash equivalents. Changes in interest rates can also affect our ability to acquire and originate loans and securities and the value of our investment portfolio. Our net investment income is affected by fluctuations in various interest rates, including SOFR and Prime rates. Increasing interest rates could have the effect of increasing our total investment income once interest rates increase above contractual interest rates floors to which our portfolio companies are subject. Conversely, we would expect the cost of our floating rate Credit Facility and unsecured notes to increase as well, offsetting the positive effect on our net interest income.
As of September 30, 2023, 100.0% of our performing debt portfolio investments bore interest at variable rates, consisting of approximately 65.0% based on SOFR and 35.0% based on Prime. As a policy, any interest above the cash cap, if applicable, as determined on an individual loan basis will accrue to principal and be treated as PIK interest. A hypothetical 200 basis point increase (decrease) in the interest rates on our variable-rate debt investments could increase our investment income by a maximum of $18.7 million and decrease our investment income by a maximum of $17.8 million, due to certain floors, on an annual basis.
Our debt borrowings under the Credit Facility bear interest at a floating rate, all other outstanding debt borrowings bear interest at a fixed rate. Borrowings under the Credit Facility bear interest on a per annum basis equal to the SOFR plus an applicable margin rate that ranges from 2.95% to 3.35% per annum depending on the Company's leverage ratio and number of eligible loans in the collateral pool. For additional information regarding the interest rate associated with each of our debt borrowings, refer to "Note 7 – Borrowings" to our financial statements in Part I, Item 1 of this Form 10-Q.
Because we currently borrow, and plan to borrow in the future, money to make investments, our net investment income would be dependent upon the difference between the rate at which we borrow funds and the rate at which we invest the funds borrowed. Accordingly, there can be no assurance that a significant change in market interest rates will not have a material adverse effect on our net investment income. In periods of rising interest rates, our cost of funds would increase, which could reduce our net investment income if there is not a corresponding increase in interest income generated by our investment portfolio.
We regularly measure exposure to interest rate risk. We assess interest rate risk and manage interest rate exposure on an ongoing basis by comparing our interest rate sensitive assets to our interest rate sensitive liabilities. We may hedge against interest rate and currency exchange rate fluctuations by using standard hedging instruments such as futures, options and forward contracts subject to the requirements of the 1940 Act. While hedging activities may insulate us against adverse changes in interest rates, they may also limit our ability to participate in benefits of lower interest rates with respect to our portfolio of investments with fixed interest rates.
In addition, any investments we make that are denominated in a foreign currency will be subject to risks associated with changes in currency exchange rates. These risks include the possibility of significant fluctuations in the foreign currency markets, the imposition or modification of foreign exchange controls and potential illiquidity in the secondary market. These risks will vary depending upon the currency or currencies involved, and may be exacerbated by the COVID-19 pandemic on foreign financial markets.
Item 4. Controls and Procedures
Evaluation of Disclosure Controls and Procedures
As of the end of the period covered by this report, we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a‑15 under the Exchange Act). Based on that evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our current disclosure controls and procedures are effective in timely alerting them to material information relating to us that is required to be disclosed by us in the reports we file or submit under the Exchange Act.
There have been no changes in our internal control over financial reporting that occurred during our most recently completed fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
60
PART II. OTHER INFORMATION
Item 1. Legal Proceedings
We and RGC are not currently subject to any material legal proceedings, nor, to our knowledge, is any material legal proceeding threatened against us. From time to time, we or RGC may be a party to certain legal proceedings in the ordinary course of business, including proceedings relating to the enforcement of our rights under contracts with our portfolio companies. Our business is also subject to extensive regulation, which may result in regulatory proceedings against us. While the outcome of any such legal proceedings cannot be predicted with certainty, we do not expect that any such proceedings will have a material effect upon our financial condition or results of operations.
Item 1A. Risk Factors.
You should carefully consider the risks described below and all other information contained in this quarterly report on Form 10-Q, including our interim financial statements and the related notes thereto, before making a decision to purchase our securities. The risks and uncertainties described below are not the only ones we may face. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition and/or operating results.
If any of the following risks actually occur, our business, financial condition or results of operations could be materially adversely affected. If that happens, you may lose all or part of your investment. Other than as set forth below, there have been no material changes known to us during the period ended September 30, 2023 to the risk factors discussed in “Risk Factors” in Part I, Item 1A of our annual report on Form 10-K for the year ended December 31, 2022, filed with the SEC on March 2, 2023.
Our business and our portfolio companies may be susceptible to economic slowdowns or recessions and to risks related to bank impairments or failures
We may borrow money, which would magnify the potential for gain or loss on amounts invested and may increase the risk for investing in us.
The use of leverage magnifies the potential for gain or loss on amounts invested and, therefore, increases the risks associated with investing in our securities. We may borrow from and issue senior debt securities to banks, insurance companies and other lenders in the future. Holders of these senior securities will have fixed dollar claims on our assets that are superior to the claims of our common stockholders, and we would expect such lenders to seek recovery against our assets in the event of a default. If the value of our assets increases, then leveraging would cause the net asset value attributable to our common stock to increase more sharply than it would have had we not leveraged. Conversely, if the value of our assets decreases, leveraging would cause net asset value to decline more sharply than it otherwise would have had we not leveraged. Similarly, any increase in our income in excess of interest payable on the borrowed funds would cause our net investment income to increase more than it would without the leverage, while any decrease in our income would cause net income to decline more sharply than it would have had we not borrowed. Such a decline could also negatively affect our ability to make dividend payments on our common stock, scheduled debt payments or other payments related to our securities.
61
Leverage is generally considered a speculative investment technique. Our ability to service any debt that we incur will depend largely on our financial performance and will be subject to prevailing economic conditions and competitive pressures. In addition, our common stockholders will bear the burden of any increase in our expenses, including our interest expense, as a result of leverage.
As a BDC, we are generally required to meet an asset coverage ratio, defined under the 1940 Act as the ratio of our gross assets (less all liabilities and indebtedness not represented by senior securities) to our outstanding senior securities, of at least 150% after each issuance of senior securities. If this ratio declines below 150%, we may not be able to incur additional debt and could be required by law to sell a portion of our investments to repay some debt when it is disadvantageous to do so, which could have a material adverse effect on our operations, and we may not be able to make distributions. The amount of leverage that we employ will depend on RGC’s and our Board of Director's assessment of market and other factors at the time of any proposed borrowing. We cannot assure you that we will be able to obtain credit at all or on terms acceptable to us. In addition, any debt facility into which we may enter would likely impose financial and operating covenants that restrict our business activities, including limitations that could hinder our ability to finance additional loans and investments or to make the distributions required to qualify as a RIC.
The following table illustrates the effect of leverage on returns from an investment in our common stock assuming various annual returns on our portfolio as of December 31, 2022, net of expenses. Leverage generally magnifies the return of stockholders when the portfolio return is positive and magnifies their losses when the portfolio return is negative. The calculations in the table below are hypothetical, and actual returns may be higher or lower than those appearing in the table below.
|
|
Assumed Return on Our Portfolio |
||||||||
|
|
(Net of Expenses) |
||||||||
|
|
-10% |
|
-5% |
|
0% |
|
5% |
|
10% |
Corresponding return to common stockholder(1) |
|
- |
|
- |
|
- |
|
|
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
Other than pursuant to our Dividend Reinvestment Plan, and except as previously reported by us on our current reports on Form 8‑K, we did not sell any securities during the period covered by this Form 10‑Q that were not registered under the Securities Act.
Item 3. Defaults Upon Senior Securities
None.
Item 4. Mine Safety Disclosures
Not applicable.
62
Item 5. Other Information
Rule 10b5-1 Disclosure
For the period covered by this Quarterly Report on Form 10-Q,
The Company has
Fees and Expenses
The following table is being provided to update as of September 30, 2023, certain information in our registration statement on Form N-2 (File No. 333-274351). The information is intended to assist you in understanding the costs and expenses that an investor in our common stock will bear directly or indirectly. We caution you that some of the percentages indicated in the table below are estimates and may vary. Except where the context suggests otherwise, whenever this Quarterly Report on Form 10-Q contains a reference to fees or expenses paid by “you,” “us,” or “the Company,” or that “we” will pay for expenses, stockholders will indirectly bear such fees or expenses as investors in us.
Stockholder transaction expenses: |
|
|
|
|
|
|
|
Sales load (as a percentage of offering price) |
|
|
|
|
% |
(1) |
|
Offering expenses (as a percentage of offering price) |
|
|
|
|
% |
(2) |
|
Dividend reinvestment plan expenses |
|
|
|
|
% |
(3) |
|
Total stockholder transaction expenses (as a percentage of offering price) |
|
|
|
|
% |
|
|
Annual expenses (as a percentage of net assets attributable to common stock): |
|
|
|
|
|
|
|
Management Fee payable under the Advisory Agreement |
|
|
|
|
% |
(4) |
|
Incentive Fee payable under the Advisory Agreement |
|
|
|
|
% |
(5) (8) |
|
Interest payments on borrowed funds |
|
|
|
|
% |
(6) (8) |
|
Other expenses |
|
|
|
|
% |
(7) (8) |
|
Total annual expenses |
|
|
|
|
% |
(8) |
63
Example
The following example demonstrates the projected dollar amount of total cumulative expenses over various periods with respect to a hypothetical investment in our common stock. In calculating the following expense amounts, we have assumed we would have no additional leverage and that our annual operating expenses would remain at the levels set forth in the table above. Transaction expenses are included in the following example.
|
|
|
1 year |
|
|
|
3 years |
|
|
|
5 years |
|
|
|
10 years |
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
You would pay the following expenses on a $1,000 investment, assuming a 5% annual return from realized capital gains |
|
$ |
|
|
|
$ |
|
|
|
$ |
|
|
|
$ |
|
|
The foregoing table is to assist you in understanding the various costs and expenses that an investor in our common stock will bear directly or indirectly. While the example assumes, as required by the SEC, a 5% annual return, our performance will vary and may result in a return greater or less than 5%. Because the Income Incentive Fee under the Advisory Agreement is unlikely to be significant assuming a 5% annual return, the example assumes that the 5% annual return will be generated entirely through the realization of capital gains on our assets and, as a result, will trigger the payment of the Capital Gains Fee under the Advisory Agreement. The Income Incentive Fee under the Advisory Agreement, which, assuming a 5% annual return, would either not be payable or have an immaterial impact on the expense amounts shown above, is not included in the example. If we achieve sufficient returns on our investments, including through the realization of capital gains, to trigger an Income Incentive Fee of a material amount, our expenses, and returns to our investors, would be higher. In addition, while the example assumes reinvestment of all dividends and distributions at net asset value, if our Board authorizes and we declare a cash dividend, participants in our dividend reinvestment plan who have not otherwise elected to receive cash will receive a number of shares of our common stock, determined by dividing the total dollar amount of the dividend payable to a participant by the market price per share of our common stock at the close of trading on the valuation date for the dividend. For more information regarding our dividend reinvestment plan, refer to "Note 9 – Net Assets" to our financial statements in Part I, Item 1 of this Form 10-Q.
This example and the expenses in the table above should not be considered a representation of our future expenses, and actual expenses (including the cost of debt, if any, and other expenses) may be greater or less than those shown.
64
Item 6. Exhibits
The following exhibits are filed as part of this report or hereby incorporated by reference to exhibits previously filed with the SEC:
3.1 |
|
|
|
3.2 |
|
|
|
3.3 |
|
|
|
31.1 |
|
|
|
31.2 |
|
|
|
32.1 |
Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002* |
|
|
32.2 |
Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002* |
|
|
101.INS |
Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document. |
|
|
101.SCH |
Inline XBRL Taxonomy Extension Schema Document |
|
|
101.CAL |
Inline XBRL Taxonomy Extension Calculation Linkbase Document |
|
|
101.DEF |
Inline XBRL Taxonomy Extension Definition Linkbase Document |
|
|
101.LAB |
Inline XBRL Taxonomy Extension Label Linkbase Document |
|
|
101.PRE |
Inline XBRL Taxonomy Extension Presentation Linkbase Document |
|
|
104 |
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
|
|
* Filed herewith.
65
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
RUNWAY GROWTH FINANCE CORP. |
|
Date: November 7, 2023 |
|
|
|
By: |
/s/ Greg Greifeld |
|
|
Greg Greifeld |
|
|
Acting Chief Executive Officer |
|
|
(Principal Executive Officer) |
|
|
|
Date: November 7, 2023 |
By: |
/s/ Thomas B. Raterman |
|
|
Thomas B. Raterman |
|
|
Acting President, Chief Financial Officer, Treasurer and Secretary |
|
|
(Principal Financial and Accounting Officer) |
66
Exhibit 31.1
CERTIFICATION PURSUANT TO
RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Greg Greifeld, as Acting Chief Executive Officer, certify that:
Date: November 7, 2023 |
|
By: |
/s/ Greg Greifeld |
|
|
|
Greg Greifeld |
|
|
|
Acting Chief Executive Officer |
Exhibit 31.2
CERTIFICATION PURSUANT TO
RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Thomas B. Raterman, as Chief Financial Officer, certify that:
Date: November 7, 2023 |
|
By: |
/s/ Thomas B. Raterman |
|
|
|
Thomas B. Raterman |
|
|
|
Chief Financial Officer |
Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Runway Growth Finance Corp. (the “Company”) on Form 10-Q for the period ending September 30, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
Date: November 7, 2023 |
|
By: |
/s/ Greg Greifeld |
|
|
|
Greg Greifeld |
|
|
|
Acting Chief Executive Officer |
Exhibit 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Runway Growth Finance Corp. (the “Company”) on Form 10-Q for the period ending September 30, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
Date: November 7, 2023 |
|
By: |
/s/ Thomas B. Raterman |
|
|
|
Thomas B. Raterman |
|
|
|
Chief Financial Officer |